Dipeptide mimics, libraries combining two dipeptide mimics with a third group, and methods for production thereof

ABSTRACT

Monovalent compounds having moieties comprising at least one amino acid side chain are bound to a core molecule, which also comprises a nucleophilic moiety bound to said core molecule. Monovalent compounds also comprise a macrocyclic ring, a nucleophilic moiety, and a spacer group. Monovalent compounds may be combined into bivalent and trivalent compounds, some of which may have a labeling tag. Methods of production of bivalent compounds and contemplated uses thereof are disclosed.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent application 60/952,149, filed Jul. 26, 2007, which is incorporated by reference as if written herein in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This work was funded, in part, through support from the National Institutes of Health, Grant Nos. MH070040 and GM076261.

BACKGROUND

Many proteins interact via two or more contact points that account for the majority of the binding energy between the two. Such a point of interaction may be termed a ‘hot-spot.’ Molecules may be designed having pharmacophores positioned with known separation to interact with these hot-spots. A molecule positioning two pharmacophores for interaction with hot spots may be termed a bivalent molecule. Bivalent compounds may have increased binding energy over similar monovalent compounds, since more than one pharmacophore may interact with the protein. Such compounds may be useful for studying protein-protein interactions, comprise a pharmaceutical lead compounds, or comprise pharmaceuticals.

For protein-protein interactions, studies have shown that amino acid side chain groups or side chains based on amino acid side chain groups contribute a majority of the binding energy, whereas main-chain carbonyl groups contribute relatively little toward the binding energy. Thus, pharmacophores bearing amino acid side chain groups or groups based on amino acid side chain groups are likely to have enhanced binding properties over compounds not having amino acid side chains. Drug leads utilizing unprotected amino acids as pharmacophores are undesirable from both a synthetic and pharmacological standpoint. In response to this need, peptidomimetics have been developed as a means to improve pharmacological properties and lessen synthetic burden. A number of different peptidomimetics have been prepared.

The ability to rapidly prepare libraries of compounds is advantageous for screening of new pharmacophores. Preparation of compound libraries is often achieved by combinatorial methods utilizing solid-phase syntheses. Solution-phase syntheses offer considerable handling advantages over solid-phase methods, but they are usually much slower than solid phase methods for production of compound libraries.

In view of the foregoing, it would be highly beneficial to design peptidomimetics having amino acid side chains or groups based on amino acid side chains, whose structures are amenable to rapid bivalent compound library syntheses by solution phase synthesis methods.

SUMMARY

In some aspects, the disclosure describes a compound whose structure is selected from the group consisting of:

R₁ and R₂ are comprised by at least one moiety comprising an amino acid side chain. R₁ and R₂ further comprise non-peptidic bonds. X1 comprises a core molecule selected from the group consisting of heteroarylenes, arylenes and heterocyclenes and a nucleophilic moiety bound to said core molecule. K₁ and K₂ comprise at least one spacer atom between said core molecule and said at least one moiety comprising an amino acid side chain

In other aspects, the disclosure describes a compound having the structure

A1 comprises a macrocyclic ring comprising at least two amino acids, wherein said at least two amino acids are bound to each other in a ring comprising at least one peptide bond. Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof. S1 comprises a spacer group having at least one carbonyl moiety, wherein S1 does not comprise glycine.

In another aspect, the disclosure describes a compound having the structure

B1 is a core molecule selected from the group consisting of heteroarylenes, arylenes, and heterocyclenes. P1 and P2 comprise an organic moiety comprising removal of a hydrogen atom from compounds disclosed herein. P1 and P2 are independently selected.

In still another aspect, the disclosure describes a compound having the structure

P3 and P4 comprise an organic moiety comprising removal of a hydrogen atom from the nitrogen atom of the piperidine or piperazine ring of compounds disclosed herein. P3 and P4 are independently selected. P5 comprises a moiety selected from the group consisting of an organic moiety comprising removal of a hydrogen atom from the nitrogen atom of the piperidine or piperazine ring of compounds disclosed herein and a labeling tag T1. P5 is selected independently of P3 and P4.

In still another aspect, the disclosure provides a method of producing a library of compounds, comprising the following steps:

1) providing wherein T1 comprises a labeling tag; 2) reacting a first equivalent of a piperazine or piperidine compound disclosed herein or morpholine in the presence of a base and a solvent; 3) removing the solvent; and 4) reacting a second equivalent of a piperazine or piperidine compound disclosed herein or morpholine in the presence of a base and a sovlent. Selection of said first equivalent and said second equivalent is conducted with the proviso that said first equivalent and said second equivalent are not both morpholine.

The disclosure also provides pharmaceutical compounds, pharmaceutical lead compounds, and pharmacological probes selected from the compounds described herein. The disclosure also provides compounds selected from the compounds described herein which demonstrate protein-protein interactions.

The foregoing has outlined rather broadly the features of the present disclosure in order that the detailed description that follows may be better understood. Additional features and advantages of the disclosure will be described hereinafter, which form the subject of the claims.

DETAILED DESCRIPTION

In the following description, certain details are set forth such as specific quantities, sizes, etc. so as to provide a thorough understanding of the present embodiments disclosed herein. However, it will be obvious to those skilled in the art that the present disclosure may be practiced without such specific details. In many cases, details concerning such considerations and the like have been omitted inasmuch as such details are not necessary to obtain a complete understanding of the present disclosure and are within the skills of persons of ordinary skill in the relevant art.

While most of the terms used herein will be recognizable to those of skill in the art, the following definitions are nevertheless put forth to aid in the understanding of the present disclosure. It should be understood, however, that when not explicitly defined, terms should be interpreted as adopting a meaning presently accepted by those of skill in the art.

“Alkyl,” as defined herein refers to groups comprising straight, branched, and cyclic substituents containing about 1 to about 20 carbons, or about 1 to about 10 carbons in some embodiments. Alkyl groups may have carbon-carbon double bonds and contain about 2 to about 20 carbons, or about 2 to about 10 carbons in some embodiments. Alkyl groups may also have carbon-carbon triple bonds and contain about 2 to about 20 carbons, or about 2 to about 10 carbons in some embodiments. In an embodiment, an alkyl group is a methyl group. Representative alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, neopentyl, tert-pentyl, isohexyl, ethenyl, propenyl, butenyl, pentenyl, acetylenely, propynyl, butynyl, pentynyl, hexynyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Alkyl groups may be substituted with heteroatoms in the carbon chain comprising the alkyl group, wherein heteroatoms include, but are not limited to oxygen, nitrogen, and sulfur. Alkyl groups may be substituted with one or more substituents, in certain embodiments one substituent, and in other embodiments three or four substituents.

“Amino acid side chain moieties,” as defined herein includes groups of atoms linked to the α-carbon of naturally-occurring amino acids and their derivatives, homologues, and analogues.

“Arylene,” as defined herein, is a monocyclic or polycyclic aromatic group having from about 5 to about 20 carbon atoms, at least one aromatic ring, and at least two substituents. In some embodiments, the arylene group has about 5 to about 12 carbon atoms. In an embodiment, the arylene is monocyclic and has 5 or 6 carbon atoms. Arylene groups may include, but are not limited to 1,2-, 1,3- and 1,4-disubstituted phenylene.

“Heteroarylene,” as defined herein, is a monocyclic or polycyclic aromatic ring having about 5 to about 15 atoms in the ring, wherein about 1 to about 5 of the atoms in the ring are heteroatoms, and said ring has at least two substituents. “Heteroatom,” as defined herein, is an atom other than carbon, including but not limited to nitrogen, oxygen, and sulfur. In an embodiment, a heteroarylene is monocyclic and has 5 or 6 atoms, wherein 1 to 3 of the atoms are heteroatoms.

“Heterocyclene,” as defined herein, is a monocyclic or polycyclic non-aromatic ring having about 5 to about 11 atoms in the ring, wherein about 1 to about 4 of the atoms in the ring are heteroatoms, and said ring has at least two substituents. Heteroatoms are atoms other than carbon that may include, but are not limited to, nitrogen, oxygen, and sulfur. In an embodiment, a heterocyclene is monocyclic and has 5 or 6 atoms, wherein 1 to 3 of the atoms are heteroatoms.

In another embodiment, a heterocyclene is monocyclic and has 6 or 7 atoms, wherein 1 to 3 of the atoms are heteroatoms. In an embodiment, a heterocyclene is monocyclic, has 6 atoms, and 2 heteroatoms.

“Macrocyclic ring,” as defined herein, is a ring having more than about 12 atoms. In an embodiment, a macrocyclic ring has more than about 14 atoms. In an embodiment, a macrocyclic ring has 14 atoms. Macrocyclic rings may contain heteroatoms.

“Non-peptidic bond,” as defined herein, is a chemical bond not comprising a peptide bond. A non-peptidic bond may be an amide bond, provided the amide bond is not between two amino acids, wherein said amide bond between two amino acids is between the backbone amino and carboxylic acid groups of said amino acids. A non-peptidic bond may be a bond between two amino acids, if said bond comprises any one other atom than the backbone amino and carboxylic acid groups.

“Peptide bond,” as defined herein, is an amide bond formed between the backbone amino and carboxylic acid groups of amino acids, peptides, proteins, and any of their derivatives or analogs.

It is to be understood that compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or a mixture thereof. Compounds containing more than one chiral center may be enantiomerically pure, or be a mixture of stereoisomeric and diastereomeric forms.

Compounds disclosed herein are substantially pure. “Substantially pure,” as disclosed herein comprises a purity assay of >85% as determined by reversed-phase HPLC and identification of a molecular ion peak or fragment thereof by mass spectrometry (MS). A substantially pure compound may be a mixture of stereoisomers, which may be further separable if desired.

In a general aspect of the disclosure, a compound having the structure selected from the group consisting of:

is described. R₁ and R₂ are comprised by at least one moiety comprising an amino acid side chain, and R₁ and R₂ further comprise non-peptidic bonds. X1 comprises a core molecule selected from the group consisting of heteroarylenes, arylenes, and heterocyclenes. A nucleophilic moiety also comprises X1 with the nucleophilic moiety bound to the core molecule in some manner. X1 may be further comprised by at least one 1,2,3-triazine moiety bound to the core molecule. In an embodiment, two 1,2,3-triazine moieties are bound to the core molecule. K₁ and K₂ comprise at least one spacer atom between the core molecule and the at least one moiety comprising an amino acid side chain. Spacer atoms may comprise chains or rings of atoms and may contain single bonds, double bonds, triple bonds, and combinations thereof. Compounds comprising this aspect of the disclosure may be considered diamino acid peptidomimetics, since the compounds mimic two amino acids present in protein structures.

Amino acid side chain moieties, which comprise R₁ and R₂, may include a structural fragment including, but not limited to:

Structural fragment, as used hereinabove, refers to a grouping of atoms comprising the amino acid side chain moieties listed hereinabove. R₁ and R₂ may be comprised solely by the amino acid side chain moieties comprising a structural fragment, or the structural fragment may be part of a larger grouping of atoms comprising R₁ and R₂. The point of attachment to the amino acid side chain moieties is indicated by the bond disconnection shown in the listing of moieties hereinabove. R₁ and R₂ may be independently selected and comprise any of the amino acid side chain moieties listed hereinabove.

The nucleophilic moiety comprising X1 comprises a moiety selected from piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof. In an embodiment of the disclosure, the nucleophilic moiety is piperidine. In another embodiment of the disclosure, the nucleophilic moiety is piperazine. The nucleophilic moiety may be bound directly to X1 in an embodiment. In another embodiment, the nucleophilic moiety may be bound to X1 through at least one spacer atom. The at least one spacer atom may comprise R₁ or R₂ or comprise additional atoms bound to X1. The nucleophilic moiety may provide a synthetic handle for further synthetic manipulation of the compounds.

The core molecule comprising X1 may be an aromatic ring in some embodiments, a heteroaromatic ring in other embodiments, or a heterocyclic ring in still other embodiments. Aromatic rings may include, but are not limited to, a 1,2-substituted phenyl ring, a 1,3-substituted phenyl ring, and a 1,4-substituted phenyl ring. An aromatic ring may be trisubstituted, such as a 1,2,4-substituted phenyl ring, a 1,2,5-substituted phenyl ring, a 1,2,3-substituted phenyl ring, and a 1,3,5-substituted phenyl ring. An aromatic ring may be tetrasubstituted, such as a 1,2,3,4-substituted phenyl ring, a 1,2,3,5-substituted phenyl ring, and a 1,2,4,5-substituted phenyl ring. An aromatic ring may be pentasubstituted, such as a 1,2,3,4,5-substituted phenyl ring. An aromatic ring may be hexasubstituted, such as a 1,2,3,4,5,6-substituted phenyl ring. A heteroaromatic ring may include, but is not limited to, a 1,2,3-triazole ring, a 1,3,4-oxadiazole ring, and a pyridine ring. A heterocyclic ring may include, but is not limited to a diketopiperazine ring. In embodiments of the disclosure, derivatives and analogs of any of these rings are contemplated.

In one aspect of the disclosure, a compound having the structure

is described, wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₁ and R₂ are defined as detailed hereinabove.

In one aspect of the disclosure, a compound having the structure

is described, wherein Z1, R₁ and R₂ are defined as detailed hereinabove. Z2 is a moiety that may include, but is not limited to —CH₂—, —CH₂CH₂— and —CH₂CH₂O—, and n1 is an integer from 1-20. In an embodiment of the disclosure, a compound having the structure

is described, wherein Z1, R₁ and R₂ are defined as detailed hereinabove.

In another aspect of the disclosure, a compound having the structure

is described wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₁ and R₂ are defined as detailed hereinabove. Z3 and Z4 comprise moieties independently selected from the group consisting of CO₂R₃, CONR₄R₅, and CH₂OH, wherein R₃ is H or alkyl, R₄ is H or alkyl, and R₅ is H or alkyl. R₄ and R₅ are selected independently from one another. In an embodiment, the compound has the structure

wherein Z1, R₁, and R₂ are defined as detailed hereinabove. R₆ and R₇ are independently selected from the group consisting of hydrogen and alkyl. In certain embodiments of the disclosure, R₆ is methyl and R₇ is H. In other embodiments of the disclosure, R₆ is H and R₇ is methyl. In still other embodiments of the disclosure, both R₆ and R₇ are methyl.

In another aspect of the disclosure, a compound having a structure

is described, wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₁ and R₂ are defined as detailed hereinabove. In an embodiment, a compound having the structure

is described, wherein Z1, R₁ and R₂ are defined as detailed hereinabove. Z2 is a moiety that may include, but is not limited to, —CH₂—, —CH₂CH₂— and —CH₂CH₂O—, and n1 is an integer from 1-20. In an embodiment of the disclosure, a compound having the structure

is described, wherein Z1, R₁ and R₂ are defined as detailed hereinabove

In another aspect of the disclosure, a compound having the structure

is described, wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₁ and R₂ are defined as detailed hereinabove. R₈, and R₉ are independently selected from the group consisting of hydrogen and alkyl. In an embodiment, both R₈ and R₉ are hydrogen. In another embodiment, both R₈ and R₉ are methyl groups.

In another aspect of the disclosure, a compound having the structure

is described, wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₁ and R₂ are defined as detailed hereinabove. R₁₀ and R₁₁ are independently selected from the group consisting of hydrogen and alkyl. In an embodiment, both R₁₀ and R₁₁ are hydrogen.

In another aspect of the disclosure, a compound having the structure

is described, wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₁ and R₂ are defined as detailed hereinabove.

In still another aspect of the disclosure a compound having the structure

is described, wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₁ and R₂ are defined as detailed hereinabove.

In the embodiments described hereinabove, the compounds may have the structure selected from the group, including but not limited to:

A general aspect of the disclosure describes compounds having the structure

wherein A1 comprises a macrocyclic ring comprising at least two amino acids. The at least two amino acids are bound to each other in a ring comprising at least one peptide bond. Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof. S1 comprises a spacer group having at least one carbonyl moiety, wherein S1 does not comprise glycine. In certain embodiments, the compound has a structure selected from the group of compounds, including but not limited to:

Compounds produced hereinabove may be useful as monovalent diamino acid mimics. The compounds may also be useful as pharmaceuticals or pharmaceutical leads. They demonstrate utility in that two of these monovalent amino acid mimics may be assembled into one molecule to give a bivalent amino acid mimic. The monovalent compounds may be assembled into bivalent compounds using a their appended nucleophile in a non-limiting example. In practicing the disclosure to form monovalent and bivalent amino acid mimics, the compounds disclosed hereinabove may be synthesized in a protected form. Such a protected form may comprise protecting groups known to those skilled in the art. In non-limiting examples, amino groups may be protected with a tert-butoxycarbonyl group and carboxylic acids may be protected as t-butyl esters. Other protecting groups may be more advantageous for use with certain moieties, and the utility of substituting different protecting groups for a given situation will be evident to those skilled in the art.

The compounds disclosed hereinabove may comprise a fragment of a larger molecule, wherein the fragment comprises removal of a hydrogen atom from the secondary nitrogen of the piperidine or piperazine ring of any of the compounds. Said fragment may be bonded to any other molecule conceivable to one skilled in the art. In an embodiment, the compounds disclosed hereinabove may comprise a bivalent amino acid mimic.

An advantage of the compounds disclosed hereinabove as monovalent amino acid mimics is that the syntheses of most of the compounds may be conducted directly from amino acid starting materials. This feature allows a wide range of amino acid side chains to be incorporated into the monovalent compounds. Through methods known to those skilled in the art, side chains that are analogs, derivatives, or homologues of naturally-occurring amino acid side chains may be incorporated into the molecules as well. In another aspect, amino acid side chains may be incorporated into the compounds to mimic proteins that are involved in any protein-protein interaction of interest. In a non-limiting example, the amino acid side chains may be those derived from the group including, but not limited to, Trp, Arg, Tyr, Lys, Glu, Ser, Asn and Leu. Another advantage of the monovalent amino acid mimics is that the amino acid side chains may be incorporated at a variety of separations and presentation angles by choice of the core molecule. Further, the organic framework is relatively rigid. These differences in distance and presentation angle may correspond to proximal amino acids in any secondary structural element, such as turns, helices, sheets, and loops, in a protein of interest. In yet another advantage, syntheses of the compounds do not require amino acid protection. Yet another advantage of the compounds, is that they contain a nucleophilic group, which allows the monovalent compounds to be assembled into bivalent compounds, again without the requirement for protecting groups. Said nucleophilic group may or may not influence the pharmacological or biological activity in the monovalent or bivalent compounds. In summary, the compounds present the following advantages: 1) convenient preparation of a plurality of amino acid side chains and derivatives, 2) rigid frameworks to which the amino acid side-chains are bound, 3) variable separation and presentation angles of the amino acid side chains, allowing mimicking of various protein secondary structures, and 4) incorporation of a nucleophilic group which allows assembly of the monovalent compounds into divalent compounds.

Another aspect of the present disclosure is a compound having the structure

wherein B1 is a core molecule selected from the group consisting of heteroarylenes, arylenes, and heterocyclenes. P1 and P2 are independently selected and comprise an organic moiety comprising removal of a hydrogen atom from any of the compounds disclosed hereinabove. The compound may be further comprised by a labeling tag T1 which is bound to B1. In embodiments of the disclosure, T1 may be a group such as a fluorescein tag, a biotin tag, a polyether tag, or a 1,2,3-triazole-functionalized polyether tag, in non-limiting examples. The compound may also be further comprised by a third organic moiety comprising removal of a hydrogen atom from the compounds disclosed hereinabove bound to B1, wherein said third organic moiety is selected independently of P1 and P2.

In another general aspect of the disclosure, a compound having the structure

is described, wherein P3 and P4 comprise an organic moiety comprising removal of a hydrogen atom from the nitrogen atom of the piperidine or piperazine ring of the compounds disclosed hereinabove. P3 and P4 are independently selected. P5 comprises a moiety selected from the group consisting of an organic moiety comprising removal of a hydrogen atom from the nitrogen atom of the piperidine or piperazine ring of the compounds disclosed hereinabove and a labeling tag T1. P5 is selected independently of P3 and P4. In an embodiment, the compound has the structure

wherein P3, P4, and T1 are defined as described hereinabove. In a further embodiment, at least one of P3 and P4 may further comprise a morpholinyl group (structure p below), with the proviso that both P3 and P4 are not a morpholinyl group.

In embodiments wherein there is a labeling tag T1, T1 may be a group such as a fluorescein tag, a biotin tag, a polyether tag, or a 1,2,3-triazole-functionalized polyether tag, in non-limiting examples. In certain embodiments, the labeling tag T1 may be selected from the group, including but not limited to the following structures:

These labeling tags are representative of the groups that may be useful for tagging the library and should not be considered limiting of the disclosure. For example, fragment 1, may be useful for fluorescence detection assays. Fragment 2 may be useful in strepavidin-based assays. Fragment 3 may be useful for conveying improved water solubility. Fragment 3 also bears functionality beneficial for synthesizing fragment 4, which has a 1,2,3-triazine moiety appended to its polyether chain. Fragment 4 may be useful for impregnation of the compounds comprising fragment 4 into a liposome structure.

Compounds comprising P3, P4, and T1 may comprise a combinatorial library. By way of non-limiting example, an exemplary member of the library of bivalent compounds may be made from a P3 fragment comprising removal of a hydrogen atom from the piperazine ring of b, a P4 fragment comprising removal of a hydrogen atom from the piperazine ring of d, and a labeling tag comprising 1. Such a library member has the structure:

The fragments comprising P3 and P4 may be chosen from any compound disclosed hereinabove, with the proviso that both P3 and P4 are not morpholinyl. Further any valid combination of P3 and P4 may be combined with any combination of T1. Members of the library may be expressed in the shorthand form P3P4T1, wherein P3, P4, and T1 describe the individual fragments bound to the central triazine core comprising the library. P3 may be selected from the group including, but not limited to, a, A, b, B, C, C, d, D, e, E, f, F, g, G, h, H, i, I, j, J, k, K, l, L, m, M, n, N, o, O, p, q, Q, r, R, s, S, t, T, u, U, v, V, w, W, x, X, y, Y, z, Z, a′, A′, b′, B′, c′, C′, d′, D′, e′, E′, f′, F′, g′, G′, h′, H′, i′, I′, j′, J′, k′, K′, l′, L′, m′, M′, n′, N′, o′, O′, p′, P′, q′, Q′, r′, R′, s′, S′, t′, T′, u′, U′, v′, V′, w′, W′, x′, X′, y′, Y′, z′, Z′, a″, A″, b″, B″, c″, C″, d″, D″, e″, E″, f″, F″, g″, G″, h″, H″, i″, I″, j′, J″, k″, K″, l″, L″, m″, M″, n″, N″, o″, O″, p″, P″, q″, Q″, r″, R″, s″, S″, t″, T″, u″, U″, v″, V″, w″, W″, x″, X″, y″, Y″, z″, Z″, a′″, A′″, b′″, B′″, c′″, C′″, d′″, D′″, e′″, E′″, f′″, F′″, g′″, G′″, h′″, H′″, i′″, I′″, j′″, J′″, k′″, K′″, l′″, L′″, m′″, M′″, n′″, N′″, o′″, O′″, p′″, P′″, q′″, Q′″, r′″, R′″, s′″, S′″, t′″, T′″, u′″, U′″, v′″, V′″, w′″, W′″, x′″, X′″, y′″, Y′″, z′″, Z′″, a″″, A″″, b″″, B″″, c″″, C″″, d″″, D″″, e″″, and E″″. P4 may be selected from the group including, but not limited to, a, A, b, B, c, C, d, D, e, E, f, F, g, G, h, H, i, I, j, J, k, K, l, L, m, M, n, N, o, O, p, q, Q, r, R, s, S, t, T, u, U, v, V, w, W, x, X, y, Y, z, Z, a′, A′, b′, B′, c′, C′, d′, D′, e′, E′, f′, F′, g′, G′, h′, H′, i′, I′, j′, J′, k′, K′, l′, L′, m′, M′, n′, N′, o′, O′, p′, P′, q′, Q′, r′, R′, s′, S′, t′, T′, u′, U′, v′, V′, w′, W′, x′, X′, y′, Y′, z′, Z′, a″, A″, b″, B″, c″, C″, d″, D″, e″, E″, f″, F″, g″, G″, h″, H″, i″, I″, j″, J″, k″, K″, l″, L″, m″, M″, n″, N″, o″, O″, p″, P″, q″, Q″, r″, R″, s″, S″, t″, T″, u″, U″, v″, V″, w″, W″, x″, X″, y″, Y″, z″, Z″, a′″, A′″, b′″, B′″, c′″, C′″, d′″, D′″, e′″, E′″, f′″, F′″, g′″, G′″, h′″, H′″, i′″, I′″, j′″, J′″, k′″, K′″, l′″, L′″, m′″, M′″, n′″, N′″, o′″, O′″, p′″, P′″, q′″, Q′″, r′″, R′″, s′″, S′″, t′″, T′″, u′″, U′″, v′″, V′″, w′″, W′″, x′″, X′″, y′″, Y′″, z′″, Z′″, a″″, A″″, b″″, B″″, c″″, C″″, d″″, D″″, e″″, and E″″. T1 may be selected from the group including, but not limited to, 1, 2, 3, and 4. All allowable combinations may comprise the library. For the non-limiting example presented hereinabove, the shorthand notation describing the library compound is bd1.

In another general aspect, the present disclosure provides a method of producing a library

of compounds comprising: 1) providing wherein T1 comprises a labeling tag; 2) reacting a first equivalent of any of the monovalent compounds described hereinabove or morpholine with the compound of step 1 in the presence of a base and a solvent; 3) removing the solvent; and 4) reacting a second equivalent of any of the monovalent compounds described hereinabove or morpholine with the compound produced in step 2 of the method. Selection of said first equivalent and said second equivalent is conducted with the proviso that said first equivalent and said second equivalent are not both morpholine. In certain embodiments of the method, the base is potassium carbonate. In certain embodiments of the method, T1 is selected from the group including, but not limited to

The method used to prepare the library of bivalent compounds is advantageous in that it is an entirely solution phase method. An additional advantage of the method is that the intermediate produced in step 2 may generally be used without further purification following removal of the solvent in step 3. Finally, the library may be synthesized from monovalent fragments comprising the monovalent compounds hereinabove, wherein the amino acid side chain moieties of the monovalent compounds do not require protection. It is further notable that the nucleophilic group comprising the monovalent compounds was designed specifically to ensure chemoselective reaction over the protein amino acid side chains. Further, the method utilizes different solvents in steps 2 and 4 to ensure monoaddition to the triazine core during coupling of the first monovalent compound.

Any of the monovalent and bivalent compounds described hereinabove and derivatives thereof may be pharmaceuticals. Any of the monovalent and bivalent compounds described hereinabove may pharmaceutical leads. A derivative or analog of a pharmaceutical lead may be a pharmaceutical. In another embodiment of the disclosure, compounds having a labeling tag may be useful for conducting pharmacological assays. In another embodiment, compounds having a labeling tag may be pharmacological probes. For example, a non-limiting use of the monovalent and divalent compounds may comprise demonstrating protein-protein interactions.

The compounds disclosed hereinabove have been designed to mimic certain proteins implicated in protein-protein interactions of particular interest. For instance, certain monovalent compounds have been designed with side-chains that correspond to amino acid residues at putative ‘hot-spots’ for the neurotrophins (NGF, BDNF, NT-3, NT-4) interacting with their receptors (TrkA, TrkB, TrkC, and p75), for the tumor necrosis factors (TNFα and TNFβ) interacting with their receptors (including p55 and p75), and for the so called “BH3-only proteins” (Bad, Bim, Bid, and Noxa) interacting with other Bcl2 proteins (eg Bcl2, Mcl1, BclW, BclB, Bax, Bak and Bok). These protein targets are merely exemplary and are not meant to be limiting of the protein targets thay may interact with the compounds described in the disclosure.

EXAMPLES

The following experimental examples are included to demonstrate particular aspects of the present disclosure. It should be appreciated by those of skill in the art that the methods described in the examples that follow merely represent exemplary embodiments of the disclosure. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments described and still obtain a like or similar result without departing from the spirit and scope of the present disclosure.

Example 1 Synthesis and Characterization of Protected Monovalent Compounds

Monovalent compounds were synthesized with their amino groups protected as t-butoxycarbonyl derivatives. For compounds having carboxylic acid groups, the carboxylic acid was protected as the t-butyl ester derivative. Phenols were either protected as the t-butyl ester derivative or left unprotected. The protecting groups are removed only just prior to coupling with a with a triazine derivative to prepare a library compound. Analyses, including ¹H and ¹³C NMR, MS, and HPLC were conducted on the fully protected monovalent precursor compounds. The following experimental data was obtained:

The following general method may be used to prepare protected monovalent compounds a through o (Scheme 1). Synthesis of protected monovalent compound 1 is demonstrated in Scheme 2 as a representative example.

Characterization data for protected monovalent compounds a through o follows:

¹H NMR (300 MHz, CDCl₃) δ 5.42 (d, 1H, J=10.5 Hz), 5.28 (s, 1H), 4.56 (s, 2H), 3.67-3.29 (m, 12H), 2.36 (m, 1H), 1.04 (s, 18H), 1.02-0.78 (m, 8H); ¹³C NMR (75 MHz, CDCl₃) δ 166.9, 156.2, 154.6, 145.5, 121.7, 80.8, 79.5, 64.7, 46.3, 44.0 (b), 42.5, 40.5, 38.2, 28.7, 28.5, 28.4, 26.3, 25.0, 24.7, 15.9, 10.6; MS (ESI, m/z) 531 (M+Li)⁺.

¹H NMR (300 MHz, CDCl₃) δ 7.48 (s, 1H), 5.21 (s, 2H), 4.60 (s, 1H), 3.61-3.52 (m, 8H), 3.12 (m, 2H), 2.75 (t, 2H, J=7.5 Hz), 1.71 (m, 2H), 1.55 (m, 2H), 1.52 (s, 9H), 1.43 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 164.0, 156.2, 154.6, 148.4, 122.7, 80.9, 79.3, 51.2, 45.3, 43.8 (b), 42.4, 40.5, 29.8, 28.7, 28.6, 26.7, 25.5; MS (ESI, m/z) 467 (M+H)⁺.

¹H NMR (300 MHz, CDCl₃) δ 8.75 (b, 1H), 7.71 (s, 1H), 5.40 (d, 1H, J=10.5 Hz), 3.67-3.04 (m, 8H), 3.02 (t, 2H, J=7.2 Hz), 2.74 (t, 2H, 7.2 Hz), 1.23 (s, 9H), 0.97-0.76 (m, 8H); ¹³C NMR (75 MHz, CDCl₃) δ 176.4, 167.0, 154.8, 147.0, 120.6, 80.9, 63.6, 46.3, 44.0 (b), 42.5, 38.1, 33.6, 28.5, 24.7, 21.1, 15.9, 10.7; MS (ESI, m/z) 422 (M−H)⁺.

¹H NMR (300 MHz, CD₃OD) δ 7.75 (b, 1H), 5.45 (s, 2H), 3.82 (t, 2H, J=6.3 Hz), 3.60-3.52 (m, 8H), 2.91 (t, 2H, J=6.3 Hz), 1.47 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 164.1, 154.6, 146.2, 123.7, 80.9, 61.7, 51.1, 45.4, 43.8 (b), 42.4, 31.2, 28.6; MS (ESI, m/z) 340 (M+H)⁺.

¹H NMR (300 MHz, CD₃OD) δ 7.74 (s, 1H), 5.49 (s, 2H), 4.00 (m, 1H), 3.60-3.54 (m, 8H), 2.81 (d, 2H, J=6.3 Hz), 1.47 (s, 9H), 1.20 (d, 3H, J=6.3 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 164.1, 154.6, 145.8, 123.9, 80.9, 67.3, 51.1, 45.4, 44.0 (b), 42.4, 35.2, 28.6, 23.2; MS (ESI, m/z) 360 (M+Li)⁺.

¹H NMR (300 MHz, CDCl₃) δ 7.74 (s, 1H), 5.28 (d, 1H, 7.5 Hz), 3.89 (s, 2H), 3.72-3.17 (m, 8H), 2.94 (m, 4H), 2.55 (m, 1H), 1.42 (s, 9H), 0.99 (m, 3H), 0.74 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 166.9, 154.6, 146.2, 120.7, 80.8, 65.1, 61.0, 46.3, 44.2 (b), 43.6, 42.5, 32.2, 28.6, 19.7, 18.6; MS (ESI, m/z) 382 (M+H)⁺.

¹H NMR (300 MHz, CD₃OD) δ 7.98 (s, 1H), 5.74 (d, 1H, J=5.7 Hz), 4.83 (s, 2H), 4.46 (m, 1H), 3.66-3.12 (m, 8H), 3.05 (t, 2H, J=6.6 Hz), 2.73 (m, 2H), 1.67 (m, 2H), 1.54 (m, 2H), 1.48 (s, 9H), 1.44 (s, 9H), 1.13 (d, 3H, J=6.3 Hz); ¹³C NMR (75 MHz, CD₃OD) δ 167.2, 158.3, 156.0, 148.3, 124.0, 81.6, 79.7, 68.3, 66.1, 46.8, 43.5 (b), 43.3, 40.9, 30.3, 28.8, 28.6, 27.6, 25.9, 20.1; MS (ESI, m/z) 511 (M+H)⁺.

¹H NMR (300 MHz, CD₃OD) δ 7.93 (s, 1H), 5.88 (t, 1H, J=7.2 Hz), 4.05 (m, 1H), 3.71-3.05 (m, 8H), 2.86 (m, 2H), 2.84 (d, 2H, J=6.3 Hz), 2.14 (m, 2H), 1.39 (m, 11H), 1.27 (m, 11H), 1.20 (d, 3H, J=6.3 Hz); ¹³C NMR (75 MHz, CD₃OD) δ 167.5, 157.4, 155.0, 145.2, 122.4, 80.6, 78.7, 66.8, 59.9, 45.6, 43.6 (b), 42.3, 39.6, 35.0, 31.9, 29.2, 27.7, 27.5, 22.7, 21.9; MS (ESI, m/z) 531 (M+Li)⁺.

¹H NMR (300 MHz, CD₃OD) δ 7.95 (s, 1H), 6.00 (q, 1H, J=6.6 Hz), 3.68-3.34 (m, 10H), 2.83 (t, 2H, J=7.5 Hz), 1.80 (m, 2H), 1.76 (d, 3H, J=6.6 Hz), 1.74 (s, 9H), 1.54 (s, 9H); ¹³C NMR (75 MHz, CD₃OD) δ 168.0, 163.5, 156.5, 155.0, 153.0, 147.2, 121.5, 83.3, 80.6, 79.2, 55.7, 45.4, 44.0 (b), 42.3, 40.0, 28.7, 27.4, 27.1, 22.5, 17.2; MS (ESI, m/z) 609 (M+H)⁺.

¹H NMR (300 MHz, CDCl₃) δ 11.44 (s, 1H), 8.36 (s, 1H), 7.62 (s, 1H), 5.33 (d, 1H, J=9.9 Hz), 3.61-3.11 (m, 10H), 2.71 (m, 2H), 2.32 (s, 1H), 1.93 (m, 2H), 1.43 (s, 18H), 1.32 (s, 9H), 0.94 (m, 5H), 0.74 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 166.9, 163.7, 156.4, 154.5, 153.4, 147.6, 119.8, 83.2, 80.5, 79.3, 63.4, 46.2, 43.4, 42.4 (b), 38.4, 37.9, 34.0, 28.8, 28.4, 28.2, 24.6, 23.3, 15.9, 10.6; MS (ESI, m/z) 651 (M+H)⁺.

¹H NMR (3000 MHz, CD₃OD) δ 7.89 (s, 1H), 7.79 (s, 1H), 5.44 (s, 2H), 3.56-3.30 (m, 10H), 2.77 (t, 2H, J=7.5 Hz), 1.94 (m, 2H), 1.52 (s, 9H), 1.46 (s, 18H); ¹³C NMR (75 MHz, CD₃OD) δ 165.3, 163.4, 156.5, 155.0, 153.0, 147.0, 124.2, 83.3, 80.6, 79.2, 50.9, 44.7, 43.4, 42.7 (b), 42.0, 39.8, 28.8, 27.5, 27.1, 22.4; MS (ESI, m/z) 595 (M+H)⁺.

¹H NMR (300 MHz, CD₃OD) δ 7.91 (s, 1H), 5.87 (t, 1H, J=7.2 Hz), 3.72-3.33 (m, 8H), 3.04 (t, 2H, J=7.5 Hz), 2.74 (t, 2H, J=7.2 Hz), 2.18 (m, 2H), 1.69 (2 Hz); ¹³C NMR (75 MHz, CD₃OD) δ 167.4, 157.3, 154.9, 121.3, 80.5, 78.6, 59.9, 47.1, 45.6, 44.0 (b), 42.3, 39.7, 31.9, 31.6, 29.3, 27.8, 27.6, 25.0, 22.7, 22.1, 13.1; MS (ESI, m/z) 537 (M−H)⁺.

¹H NMR (300 MHz, CDCl₃) δ 7.62 (b, 1H), 7.27 (s, 1H), 5.81 (q, 1H, J=7.2 Hz), 3.75-3.20 (m, 8H), 3.03 (t, 2H, J=7.2 Hz), 2.75 (t, 2H, J=7.2 Hz), 1.68 (d, 3H, J=7.2 Hz), 1.43 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 176.4, 167.1, 154.9, 146.9, 120.6, 80.9, 55.4, 45.8, 44.0 (b), 42.6, 33.5, 28.6, 21.1, 18.9; MS (ESI, m/z) 380 (M−H)⁺.

¹H NMR (300 MHz, CDCl₃) δ 7.88 (s, 1H), 6.92 (d, 2H, J=8.4 Hz), 6.72 (d, 2H, J=8.4 Hz), 5.88 (t, 1H, J=7.8 Hz), 3.87 (t, 2H, J=6.0 Hz), 3.52-3.16 (m, 9H), 2.93 (m, 3H), 1.43 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 166.8, 156.6, 154.7, 145.7, 130.6, 125.8, 121.8, 116.1, 81.0, 61.5, 60.6, 46.0, 43.4, 42.7(b), 42.5, 39.1, 28.6; MS (ESI, m/z) 446 (M+H)⁺.

¹H NMR (300 MHz, CD₃OD) δ 7.91 (s, 1H), 6.5.4 (s, 1H), 5.87 (t, 1H, J=7.2 Hz), 3.72-3.33 (m, 8H), 3.04 (t, 2H, J=7.5 Hz), 2.74 (t, 2H, J=7.2 Hz), 2.18 (m, 2H), 1.69 (2 Hz); ¹³C NMR (75 MHz, CD₃OD) δ 167.4, 157.3, 154.9, 121.3, 80.5, 78.6, 59.9, 47.1, 45.6, 43.6 (b), 42.3, 39.7, 31.9, 31.6, 29.3, 27.8, 27.6, 25.0, 22.7, 22.1, 13.1; MS (ESI, m/z) 523 (M+H)⁺.

The following general method may be used to prepare protected monovalent compounds q through e′ (Scheme 3). Synthesis of protected monovalent compound q is demonstrated in Scheme 4 as a representative example.

Characterization data for protected monovalent compounds q through e′ follows:

¹H NMR (500 MHz, CD₃OD) δ 8.44 (d, J=3.0 Hz, 1H), 8.34 (d, J=11.0 Hz, 1H), 8.21 (d, J=9.5 Hz, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 7.44 (d, J=7.5 Hz, 1H), 7.27 (d, J=8.0 Hz, 1H), 7.04 (t, J=7.5 Hz, 1H), 6.98-6.95 (m, 3H), 6.89 (s, 1H), 6.62 (d, J=8.5 Hz, 2H), 5.80-5.77 (m, 1H), 5.55 (dd, J=9.5, 6.0 Hz, 1H), 3.81-3.67 (m, 15H), 1.45 (s, 9H), 1.42 (s, 9H); ¹³C NMR (125 MHz, CD₃OD) δ 171.7, 170.3, 168.8, 157.7, 156.2, 147.2, 138.1, 137.8, 133.0, 131.2, 128.2, 127.4, 125.0, 124.79, 124.76, 124.5, 123.5, 123.2, 122.6, 120.1, 118.8, 116.3, 112.4, 109.3, 84.5, 81.6, 66.5, 65.2, 53.6, 44.8, 43.2, 38.2, 29.3, 28.6, 28.0; MS (MALDI) calcd for C₄₅H₅₂N₉O₈ (M+H)⁺ 846, found 846.

¹H NMR (500 MHz, CD₃OD) δ 8.53 (s, 1H), 8.36 (s, 1H), 8.27 (s, 1H), 7.84 (s, 1H), 7.72 (s, 1H), 7.45 (d, J=8.0 Hz, 1H), 7.27 (d, J=8.5 Hz, 1H), 7.21 (s, 1H), 7.04 (t, J=7.5 Hz, 1H), 6.96 (t, J=7.3 Hz, 1H), 6.90 (s, 1H), 5.80-5.77 (m, 1H), 5.49-5.46 (m, 1H), 3.77-3.38 (m, 16H), 2.98 (t, J=6.5, 2H), 2.31-2.23 (m, 2H), 1.45 (s, 9H), 1.34 (s, 9H), 1.33-1.14 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 171.6, 170.6, 170.4, 158.4, 156.2, 147.6, 138.1, 137.8, 132.9, 129.4, 128.8, 128.6, 128.1, 125.0, 124.8, 124.5, 123.5, 122.9, 122.6, 120.1, 118.8, 112.4, 109.3, 81.6, 79.8, 67.2, 65.1, 64.2, 53.6, 45.0 (br), 43.2, 40.7, 32.5, 30.1, 29.3, 28.7, 28.6, 24.0; MS (MALDI) calcd for C₄₄H₅₇N₁₀O₉ (M+H)⁺ 869 found 869.

¹H NMR (500 MHz, CDCl₃) δ 8.38 (s, 1H), 8.27 (d, J=5.0 Hz, 1H), 8.10 (s, 1H), 7.93 (s, 1H), 7.89 (s, 1H), 7.77 (s, 1H), 7.51 (d, J=7.5 Hz, 1H), 7.35 (d, J=8.0 Hz, 1H), 7.18 (t, J=7.5 Hz, 1H), 7.12 (t, J=7.5 Hz, 1H), 6.81 (s, 1H), 5.76-5.73 (m, 1H), 5.41 (dd, J=9.5, 6.0 Hz, 1H), 3.79 (s, 3H), 3.75-3.35 (m, 10H), 2.05-2.01 (m, 1H), 1.49 (s, 9H), 1.48 (s, 9H), 1.47-1.37 (m, 2H), 0.99 (d, J=3.3 Hz, 3H), 0.95 (d, J=3.3 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 169.8, 168.9, 168.8, 168.3, 154.5, 146.5, 146.3, 136.7, 136.0, 131.6, 131.5, 126.7, 124.0, 123.8, 123.2, 122.4, 120.7, 119.8, 119.7, 118.0, 111.5, 108.7, 83.6, 80.3, 63.4, 62.1, 53.2, 47.6, 43.7 (br), 42.1, 41.6, 29.0, 28.3, 27.9, 24.7, 22.6, 21.3; MS (MALDI) calcd for C₄₂H₅₄N₉O₇ (M+H)⁺ 796, found 796.

¹H NMR (300 MHz, CD₃OD) δ 8.56 (s, 1H), 8.37 (s, 1H), 8.28 (s, 1H), 7.86 (s, 1H), 7.74 (s, 1H), 7.45 (d, J=7.8 Hz, 1H), 7.28 (d, J=8.4 Hz, 1H), 7.05 (t, J=7.4 Hz, 1H), 6.97 (t, J=7.4 Hz, 1H), 6.90 (s, 1H), 5.80 (dd, J=9.3, 5.4 Hz, 1H), 5.47 (dd, J=9.9, 5.4 Hz, 1H), 3.79 (s, 3H), 3.78-3.40 (m, 10H), 2.61-2.38 (m, 2H), 2.45 (t, J=6.9 Hz, 2H), 1.47 (s, 9H), 1.46 (s, 9H), 1.41 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 171.7, 170.6, 169.2, 167.7, 155.0, 146.5, 146.0, 137.1, 136.7, 131.9, 131.9, 127.0, 123.9, 123.6, 123.4, 123.3, 122.3, 121.9, 121.5, 118.9, 117.6, 111.3, 108.2, 83.5, 80.9, 80.5, 64.0, 62.9, 52.4, 43.7 (br), 42.1, 30.9, 28.2, 27.4, 27.1, 27.0, 26.9; MS (MALDI) calcd for C₄₅H₅₈N₉O₉ (M+H)⁺ 868, found 868.

¹H NMR (500 MHz, CD₃OD) δ 9.53 (s, 1H), 8.30 (d, J=4.0 Hz, 1H), 8.19 (d, J=5.0 Hz, 1H), 7.80 (s, 1H), 7.68 (s, 1H), 7.44 (d, J=8.0 Hz, 1H), 7.26 (d, J=8.5 Hz, 1H), 7.02 (t, J=7.5 Hz, 1H), 6.95 (t, J=7.5 Hz, 1H), 6.87 (s, 1H), 5.75 (dd, J=9.5, 5.0 Hz, 1H), 5.66 (dd, J=6.0, 3.5 Hz, 1H), 4.36 (dd, J=12.0, 5.5 Hz, 1H), 4.14 (dd, J=12.5, 3.5 Hz, 1H), 3.77 (s, 3H), 3.75 (s, 3H), 3.74-3.38 (m, 10H), 1.44 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 171.6, 170.4, 169.1, 156.2, 147.2, 147.1, 138.1, 137.8, 133.0, 132.9, 128.2, 125.0, 124.9, 124.5, 123.7, 123.4, 122.6, 120.1, 118.8, 112.5, 109.4, 81.6, 66.3, 65.1, 62.8, 53.62, 53.61, 42.4 (br), 43.2, 29.3, 28.6; MS (MALDI) calcd for C₃₆H₄₂N₉O₈ (M+H)⁺ 728, found 728.

¹H NMR (500 MHz, CD₃OD) δ 8.64 (t, J=1.5 Hz, 1H), 8.51 (s, 1H), 8.38 (t, J=1.5 Hz, 1H), 7.88 (s, 1H), 7.83 (t, J=1.5 Hz, 1H), 6.96 (d, J=8.5 Hz, 2H), 6.63 (d, J=8.5 Hz, 2H), 5.57 (dd, J=10.0, 6.0 Hz, 1H), 5.44 (dd, J=11.0, 5.5 Hz, 1H), 3.77-3.38 (m, 10H), 2.28-2.22 (m, 1H), 2.10-2.04 (m, 1H), 1.47 (s, 9H), 1.46 (s, 9H), 1.43 (s, 9H), 1.42-1.39 (m, 1H), 0.98 (d, J=6.5 Hz, 3H), 0.94 (d, J=5.0 Hz, 3H); ¹³C NMR (125 MHz, CD₃OD δ 171.7, 169.6, 168.8, 157.7, 156.2, 147.5, 147.2, 138.3, 133.2, 131.2, 127.4, 125.0, 124.5, 123.2, 122.8, 116.4, 84.5, 84.4, 81.7, 66.6, 63.5, 44.0 (br), 43.3, 41.6, 38.3, 28.6, 28.11, 28.09, 26.1, 23.0, 21.5; MS (MALDI) calcd for C₄₃H₅₈N₈O₈Na (M+Na)⁺ 837, found 837.

¹H NMR (500 MHz, CDCl₃) δ 8.33 (s, 1H), 8.13 (s, 1H), 8.08 (s, 1H), 7.90 (s, 1H), 7.84 (s, 1H), 7.12 (d, J=8.0 Hz, 2H), 7.06 (d, J=8.0 Hz, 2H), 5.50 (t, J=7.3 Hz, 1H), 5.40 (dd, J=9.0, 5.0 Hz, 1H), 4.60 (s, 1H, N—H), 3.78 (s, 6H), 3.75-3.38 (m, 10H), 3.07 (br, 2H), 2.25-2.13 (m, 2H), 1.53-1.23 (m, 40H); ¹³C NMR (125 MHz, CDCl₃) δ 169.7, 169.1, 167.0, 155.9, 154.4, 151.5, 150.3, 146.8, 146.3, 136.7, 132.2, 131.5, 131.4, 129.9, 124.0, 123.8, 123.7, 121.5, 120.2, 119.8, 84.0, 83.5, 80.2, 64.6, 62.7, 53.1, 47.6, 43.5 (br), 42.1, 39.8, 38.3, 32.4, 29.2, 28.28, 28.26, 27.7, 27.6, 22.8; MS (MALDI) calcd for C₅₀H₆₈N₉O₁₂ (M+H)⁺ 988, found 988.

¹H NMR (500 MHz, CD₃OD) δ 8.60 (s, 1H), 8.50 (s, 1H), 8.37 (s, 1H), 7.88 (s, 1H), 7.83 (s, 1H), 6.97 (d, J=8.0 Hz, 2H), 6.63 (d, J=8.0 Hz, 2H), 5.57 (dd, J=10.0, 6.5 Hz, 1H), 5.48 (dd, J=9.5, 5.5 Hz, 1H), 3.77-3.39 (m, 10H), 2.60-2.56 (m, 1H), 2.49-2.42 (m, 1H), 2.26 (m, 2H), 1.47 (s, 9H), 1.46 (s, 9H), 1.43 (s, 9H), 1.42 (s, 9H); ¹³C NMR (125 MHz, CD₃OD) δ 172.9, 171.8, 168.9, 168.8, 157.7, 156.2, 147.6, 147.2, 138.3, 133.2, 133.1, 131.2, 127.4, 125.0, 124.6, 124.5, 123.3, 123.1, 116.4, 84.7, 84.5, 82.1, 81.7, 66.6, 64.1, 44.4 (br), 43.3, 38.3, 32.1, 28.6, 28.32, 28.25, 28.12, 28.10; MS (MALDI) calcd for C₄₆H₆₃N₈O₁₀ (M+H)⁺ 887, found 887.

¹H NMR (500 MHz, CD₃OD) δ 8.64 (s, 1H), 8.52 (s, 1H), 8.39 (s, 1H), 7.89 (s, 1H), 7.84 (s, 1H), 6.97 (d, J=8.0 Hz, 2H), 6.63 (d, J=8.5 Hz, 2H), 5.71 (dd, J=6.5, 4.0 Hz, 1H), 5.57 (dd, J=9.5, 6.0 Hz, 1H), 4.38 (dd, J=12.0, 6.5 Hz, 1H), 4.16 (dd, J=12.0, 3.0 Hz, 1H), 3.82 (s, 3H), 3.79-3.39 (m, 10H), 1.46 (s, 9H), 1.44 (s, 9H); ¹³C NMR (125 MHz, CD₃OD) δ 171.8, 169.1, 168.8, 157.7, 156.2, 147.3, 147.2, 138.3, 133.2, 133.1, 131.2, 127.4, 125.0, 124.55, 124.49, 123.8, 123.3, 116.3, 84.6, 81.6, 66.6, 66.4, 62.8, 53.6, 44.5 (br), 43.3, 38.3, 28.6, 28.1; MS (MALDI) calcd for C₃₇H₄₇N₈O₉ (M+H)⁺ 747, found 747.

¹H NMR (500 MHz, CDCl₃) δ 8.39 (s, 1H), 8.14 (s, 2H), 7.91 (s, 2H), 5.44-5.40 (m, 2H), 4.56 (br, 1H, N—H), 3.80 (s, 3H), 3.78-3.40 (m, 8H), 3.08 (br, 2H), 2.34-2.26 (m, 1H), 2.21-2.17 (m, 1H), 2.08-1.98 (m, 2H), 1.54-1.24 (m, 32H), 0.98 (d, J=6.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 169.8, 169.1, 168.3, 155.9, 154.5, 146.9, 146.7, 136.8, 131.7, 131.5, 124.0, 123.9, 123.8, 119.8, 119.6, 83.5, 80.3, 79.2, 62.8, 62.0, 53.1, 47.7, 43.6 (br), 42.1, 41.7, 39.9, 32.5, 29.3, 28.3, 27.9, 24.7, 22.8, 22.6, 21.3; MS (MALDI) calcd for C₄₂H₆₄N₉O₉ (M+H)⁺ 838, found 838.

¹H NMR (500 MHz, CD₃OD) δ 8.61 (s, 1H), 8.60 (s, 1H), 8.34 (s, 1H), 7.85 (s, 2H), 5.72-5.70 (m, 1H), 5.44 (dd, J=9.0, 5.5 Hz, 1H), 4.38 (dd, J=12.0, 6.0 Hz, 1H), 4.17 (d, J=9.5 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.77-3.42 (m, 8H), 3.00 (t, J=6.5 Hz, 2H), 2.37-2.25 (m, 2H), 1.58-1.19 (m, 22H); ¹³C NMR (125 MHz, CDCl₃) δ 171.6, 170.7, 169.1, 158.4, 156.2, 147.6, 147.3, 138.2, 133.1, 132.9, 125.0, 124.5, 124.4, 123.7, 122.9, 81.6, 79.8, 66.3, 64.2, 62.8, 53.6, 44.4 (br), 43.3, 40.8, 32.5, 30.2, 28.8, 28.7, 28.6, 24.1; MS (MALDI) calcd for C₃₆H₅₂N₉O₁₀ (M+H)⁺ 770, found 770.

¹H NMR (500 MHz, CDCl₃) δ 8.39 (s, 1H), 8.24 (s, 1H), 8.14 (s, 1H), 7.92 (s, 2H), 5.42 (dd, J=10.0, 5.0 Hz, 1H), 5.18 (d, J=8.5 Hz, 1H), 4.54 (br, 1H, N—H), 3.81 (s, 3H), 3.80-3.42 (m, 8H), 3.10-3.07 (m, 2H), 2.31-2.04 (m, 3H), 1.63-1.26 (m, 33H), 1.05 (d, J=6.5 Hz, 3H), 0.91 (t, J=7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 169.8, 169.1, 167.8, 155.9, 154.5, 146.9, 146.5, 136.8, 131.8, 131.5, 124.0, 123.9, 123.8, 119.9, 119.7, 83.6, 80.3, 68.4, 62.8, 53.1, 47.6, 43.4 (br), 42.1, 39.9, 38.8, 32.5, 29.3, 28.3, 27.9, 25.1, 22.8, 15.5, 10.8; MS (MALDI) calcd for C₄₂H₆₄N₉O₉ (M+H)⁺ 838, found 838.

¹H NMR (500 MHz, CD₃OD) δ 8.86 (s, 1H), 8.64 (s, 1H), 8.42 (s, 1H), 7.89 (s, 2H), 5.71 (dd, J=6.0, 3.5 Hz, 1H), 5.45 (dd, J=10.5, 5.0 Hz, 1H), 4.38 (dd, J=12.0, 6.0 Hz, 1H), 4.16 (dd, J=12.0, 3.0 Hz, 1H), 3.82 (s, 3H), 3.81-3.45 (m, 8H), 2.29-2.22 (m, 1H), 2.10-2.04 (m, 1H), 1.47 (s, 9H), 1.46 (s, 9H), 1.46-1.34 (m, 1H), 0.98 (d, J=6.5 Hz, 3H), 0.95 (d, J=6.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 171.7, 169.6, 169.0, 156.2, 147.5, 147.2, 138.2, 133.1, 133.0, 125.0, 124.5, 124.4, 123.8, 122.9, 84.4, 81.6, 66.3, 63.5, 62.8, 53.6, 44.5 (br), 43.2, 41.5, 28.6, 28.1, 26.0, 23.0, 21.5; MS (ESI) calcd for C₃₄H₄₉N₈O₈ (M+H)⁺ 697, found 697.

¹H NMR (500 MHz, CD₃OD) δ 8.66 (s, 1H), 8.62 (s, 1H), 8.44 (s, 1H), 7.90 (s, 2H), 5.50-5.44 (m, 2H), 3.82-3.45 (m, 8H), 2.60-2.55 (m, 1H), 2.48-2.44 (m, 1H), 2.27-2.22 (m, 3H), 2.10-2.04 (m, 1H), 1.48 (s, 9H), 1.47 (s, 9H), 1.46 (s, 9H), 1.42 (s, 9H), 1.41-1.34 (m, 1H), 0.98 (d, J=6.5 Hz, 3H), 0.95 (d, J=7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 172.9, 171.8, 169.6, 168.9, 156.2, 147.7, 147.6, 138.4, 133.2, 133.1, 125.0, 124.6, 123.1, 122.9, 84.7, 84.5, 82.1, 81.7, 64.1, 63.5, 44.8 (br), 43.3, 41.6, 32.1, 28.6, 28.32, 28.27, 28.12, 28.11, 26.1, 23.0, 21.5; MS (MALDI) calcd for C₃₇H₅₃N₈O₁₀ (M+H)⁺ 769, found 769.

¹H NMR (500 MHz, CD₃OD) δ 8.62 (s, 1H), 8.60 (s, 1H), 8.38 (s, 1H), 7.87 (s, 2H), 5.70 (dd, J=6.0, 3.5 Hz, 1H), 5.48 (dd, J=10.0, 5.5 Hz, 1H), 4.49 (dd, J=12.0, 6.0 Hz, 1H), 4.17 (dd, J=11.5, 3.0 Hz, 1H), 3.82 (s, 3H), 3.81-3.45 (m, 8H), 2.60-2.55 (m, 1H), 2.50-2.43 (m, 1H), 2.27 (t, J=7.3 Hz, 2H), 1.47 (s, 9H), 1.45 (s, 9H), 1.42 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 172.8, 171.7, 169.1, 168.9, 156.2, 147.7, 147.4, 138.3, 133.2, 133.0, 125.0, 124.6, 124.5, 123.8, 123.1, 84.7, 82.1, 81.6, 66.3, 64.1, 62.9, 53.6, 44.5 (br), 43.3, 32.2, 28.6, 28.3, 28.2, 28.1; MS (ESI) calcd for C₄₃H₆₅N₈O₉ (M+H)⁺ 837, found 837.

The following general methods may be used to prepare protected monovalent compounds f′ through m′ (Schemes 5 and 6). Synthesis of a protected monovalent compound from this group is demonstrated in Scheme 7 as a representative example.

Characterization data for protected monovalent compounds f′ through m′ follows:

¹H NMR (500 MHz, CDCl₃) δ 4.93 (br, 1H), 4.85 (d, 1H, J=16.1 Hz), 4.42-4.32 (m, 2H), 3.77 (d, 1H, J=1.7 Hz), 3.66 (d, 1H, J=16.1 Hz), 3.62-3.32 (m, 8H), 3.06 (s, 3H), 1.43 (s, 9H), 1.27 (d, 3H, J=6.5 Hz). ¹³C NMR (125 MHz, CDCl₃) δ 168.0, 165.4, 164.7, 154.2, 80.5, 71.2, 68.7, 52.0, 47.8, 44.4, 42.0, 36.1, 28.2, 19.7. Desired MS 399.22 (M+H). MS Found (ESI, m/z) 399.22 (M+H)

¹H NMR (500 MHz, CDCl₃) δ 5.26 (t, 1H, J=7.6 Hz), 4.69 (br, 1H), 4.03 (d, 1H, J=17.4 Hz), 3.96-3.81 (m, 3H), 3.58-3.30 (m, 6H), 3.27-3.18 (m, 2H), 3.03-2.93 (m, 2H), 2.87 (s, 3H), 1.80-1.58 (m, 2H), 1.45-1.37 (m, 2H), 1.35 (s, 9H), 1.31 (s, 9H), 1.20-1.12 (m, 2H). Desired MS 548.32 (M+Na). MS Found (ESI, m/z) 548.30 (M+Na)

¹H NMR (500 MHz, CDCl₃) δ 5.26 (t, 1H, J=7.6 Hz), 4.60 (br, 1H), 4.11 (br, 1H), 3.83 (d, 1H, J=17.6 Hz), 3.74 (d, 1H, J=4.3 Hz), 3.60-3.31 (m, 6H), 3.27-3.11 (m, 2H), 3.04-2.97 (m, 2H), 2.88 (s, 3H), 1.88-1.78 (m, 2H), 1.59-1.47 (m, 2H), 1.47-1.39 (m, 2H), 1.35 (s, 9H), 1.33 (s, 9H), 1.31-1.24 (m, 1H), 1.24-1.14 (m, 2H), 0.89 (t, 3H, J=7.3 Hz), 0.83 (d, 3H, J=6.8 Hz). ¹³C NMR (125 MHz, CDCl₃) δ 167.8, 162.9, 164.0, 155.8, 154.2, 80.1, 78.9, 66.6, 51.1, 45.6, 45.2, 41.9, 39.8, 38.6, 33.3, 29.5, 28.3, 28.2, 28.1, 26.2, 23.2, 14.5, 11.7. Desired MS 582.38 (M+H). MS Found (ESI, m/z) 582.39 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 5.22 (t, 1H, J=7.6 Hz), 4.69 (br, 1H), 4.10 (br, 1H), 3.88-3.78 (m, 2H), 3.60-3.09 (m, 8H), 3.05-2.96 (m, 2H), 2.89 (s, 3H), 2.30-2.17 (m, 2H), 2.13-2.04 (m, 1H), 1.95-1.85 (m, 1H), 1.85-1.76 (m, 1H), 1.67-1.57 (m, 1H), 1.49-1.28 (m, 29H), 1.23-1.12 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 171.1, 167.6, 165.6, 163.5, 155.8, 154.2, 81.0, 80.1, 78.8, 61.6, 51.2, 45.2, 45.0, 41.9, 39.8, 32.2, 30.3, 29.5, 28.2, 28.1, 28.0, 27.9, 26.3, 23.0. Desired MS 676.40 (M+H). MS Found (ESI, m/z) 676.40 (M+H)

¹H NMR (500 MHz, CDCl₃) δ 6.76 (t, 1H, J=5.6 Hz), 4.83 (d, 1H, J=4.8 Hz), 4.67 (d, 1H, J=16.3 Hz), 4.40-4.33 (m, 2H), 3.77 (d, 1H, J=1.9 Hz), 3.68 (d, 1H, J=16.3 Hz), 3.55-3.49 (m, 2H), 3.42-3.32 (m, 6H), 3.17 (q, 2H, J=6.7 Hz), 3.04 (s, 3H), 2.31-2.15 (m, 4H), 1.59-1.51 (m, 2H), 1.42 (s, 9H), 1.32-1.17 (m, 15H). ¹³C NMR (125 MHz, CDCl₃) δ 171.9, 167.4, 167.0, 164.9, 154.5, 80.3, 71.6, 68.6, 51.9, 49.4, 45.3, 41.2, 39.7, 36.2, 33.2, 29.1, 29.1, 29.0, 29.0, 28.3, 26.6, 25.1, 20.1. Desired MS 582.38 (M+H). MS Found (ESI, m/z) 582.38 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 6.22 (t, 1H, J=5.6 Hz), 4.82-4.74 (m, 1H), 4.71 (t, 1H, J=7.8 Hz), 4.07 (d, 1H, J=17.3 Hz), 3.87-3.79 (m, 2H), 3.50-3.44 (m, 2H), 3.35-3.25 (m, 6H), 3.15-2.94 (m, 4H), 2.87 (s, 3H), 2.28-2.04 (m, 5H), 1.96-1.81 (m, 2H), 1.63-1.38 (m, 5H), 1.35 (s, 9H), 1.33 (s, 9H), 1.31 (s, 9H), 1.24-1.09 (m, 16H). ¹³C NMR (125 MHz, CDCl₃) δ 171.6, 171.1, 168.6, 166.0, 163.2, 155.8, 154.3, 80.9, 80.0, 78.7, 61.6, 55.6, 45.5, 45.2, 41.0, 39.8, 39.3, 38.4, 33.1, 32.1, 30.2, 29.3, 29.2, 29.1, 29.1, 28.9, 28.2, 28.1, 27.8, 26.9, 26.5, 26.5, 25.0, 23.0. Desired MS 837.56 (M+H). MS Found (ESI, m/z) 837.57 (M+H).

¹³C NMR (125 MHz, CDCl₃) δ 171.7, 168.8, 164.4, 163.4, 155.9, 154.4, 80.1, 79.1, 78.9, 55.4, 51.6, 45.6, 45.2, 41.1, 39.3, 33.2, 33.0, 29.3, 29.2, 29.2, 29.2, 29.2, 29.0, 28.3, 28.2, 28.2, 26.7, 26.6, 25.1, 22.8. Desired MS 709.48 (M+H). MS Found (ESI, m/z) 709.47 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 6.30 (t, 1H, J=5.0 Hz), 4.75-4.69 (m, 2H), 4.07 (d, 1H, J=17.5 Hz), 3.83 (d, 1H, J=17.5 Hz), 3.76 (d, 1H, J=4.1 Hz), 3.50-3.44 (m, 2H), 3.35-3.25 (m, 6H), 3.15-2.94 (m, 4H), 2.86 (s, 3H), 2.21 (t, 2H, J=7.5 Hz), 1.88-1.76 (m, 2H), 1.57-1.38 (m, 6H), 1.35 (s, 9H), 1.31 (s, 9H), 1.29-1.09 (m, 17H), 0.88 (t, 3H, J=7.2 Hz), 0.80 (d, 3H, J=6.8 Hz). ¹³C NMR (125 MHz, CDCl₃) δ 171.6, 168.8, 165.2, 163.7, 155.8, 154.3, 80.0, 78.8, 66.4, 55.6, 46.0, 45.1, 41.0, 39.8, 39.2, 38.4, 33.1, 33.1, 29.3, 29.2, 29.1, 29.1, 28.9, 28.2, 28.1, 26.9, 26.5, 26.1, 25.0, 23.1, 14.3, 11.7. Desired MS 765.54 (M+H). MS Found (ESI, m/z) 765.54 (M+H).

The following general method may be used to prepare protected monovalent compounds n′ through g″ (Schemes 8 and 9). Synthesis of protected monovalent compound v′ is demonstrated in Scheme 10 as a representative example.

Characterization data for protected monovalent compounds n′ through g″ follows:

¹H NMR (500 MHz, CDCl₃) δ 6.59 (d, 1H, J=8.2 Hz), 5.42-5.36 (m, 1H), 5.22 (d, 1H, J=8.5 Hz), 4.98-4.89 (m, 1H), 4.65 (br, 1H), 4.10 (br, 2H), 3.78 (dd, 1H, J=3.2, 9.4 Hz), 3.15-2.94 (dd, 1H, J=3.9, 9.4 Hz), 3.12-2.99 (m, 2H), 2.81-2.65 (br, 2H), 2.39-2.30 (m, 1H), 1.94-1.75 (m, 4H), 1.70-1.57 (m, 2H), 1.51-1.31 (m, 31H), 1.06 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.2, 167.1, 165.4, 156.1, 155.0, 154.6, 80.3, 80.0, 79.6, 79.1, 73.8, 62.1, 46.9, 46.5, 42.9, 39.9, 33.2, 29.4, 28.4, 28.4, 28.3, 28.2, 27.2, 22.3. Desired MS 719.44 (M+Na). MS Found (ESI, m/z) 719.42 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.77 (br, 1H), 5.32-5.23 (m, 2H), 4.98-4.89 (m, 1H), 4.70 (br, 1H), 4.09 (br, 2H), 3.12-3.01 (m, 2H), 2.72 (br, 2H), 2.41-2.17 (m, 4H), 2.12-2.02 (m, 1H), 1.96-1.74 (m, 4H), 1.69-1.55 (m, 2H), 1.52-1.32 (m, 40H). ¹³C NMR (125 MHz, CDCl₃) δ 174.4, 172.2, 167.3, 166.4, 156.1, 155.1, 154.6, 81.2, 80.4, 79.6, 79.1, 47.1, 45.3, 42.9, 39.9, 33.2, 31.2, 29.4, 28.5, 28.4, 28.4, 28.3, 28.3, 28.0, 22.3. Desired MS 761.45 (M+Na). MS Found (MALDI, m/z) 761.06 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.95 (br, 1H), 5.66-5.58 (m, 1H), 5.24-5.13 (m, 1H), 5.03-4.93 (m, 1H), 4.73-4.63 (m, 1H), 4.25-4.05 (br, 2H), 3.16-3.06 (m, 2H), 3.06-2.97 (m, 1H), 2.88 (ddd, 1H, J=2.3, 5.2, 16.5 Hz), 2.78 (br, 2H), 2.35 (tt, 1H, J=3.7, 11.5 Hz), 2.00-1.79 (m, 4H), 1.73-1.62 (m, 2H), 1.57-1.36 (m, 40H). ¹³C NMR (125 MHz, CDCl₃) δ 174.0, 169.6, 167.4, 165.6, 156.1, 155.0, 154.6, 82.3, 80.4, 79.6, 79.2, 47.0, 43.0, 42.2, 40.0, 37.6, 33.4, 33.2, 29.4, 28.4, 28.3, 28.3, 28.0, 22.3, 22.2. Desired MS 747.44 (M+Na). MS Found (MALDI, m/z) 747.16 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.92 (d, 2H, J=8.5 Hz), 6.85 (d, 2H, J=8.5 Hz), 6.34 (d, 1H, J=8.2 Hz), 5.58-5.51 (m, 1H), 5.22 (d, 1H, J=8.5 Hz), 4.96-4.86 (m, 1H), 4.69 (br, 1H), 4.05 (br, 2H), 3.21 (dd, 1H, J=6.2, 14.0 Hz), 3.15-3.01 (m, 3H), 2.74-2.60 (br, 2H), 2.21 (tt, 1H, J=3.7, 11.5 Hz), 1.91-1.60 (m, 4H), 1.60-1.30 (m, 33H), 1.28 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.0, 171.2, 167.3, 166.2, 156.1, 155.1, 154.6, 129.8, 129.7, 124.3, 80.4, 79.2, 78.6, 47.0, 45.5, 42.9, 39.9, 38.7, 33.1, 29.4, 28.8, 28.6, 28.4, 28.4, 28.3, 28.1, 22.3. Desired MS 795.47 (M+Na). MS Found (MALDI, m/z) 795.17 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.53 (d, 1H, J=8.6 Hz), 5.44 (dt, 1H, J=3.5, 8.6 Hz), 5.18 (d, 1H, J=9.2 Hz), 4.98-4.90 (m, 11H), 4.14 (br, 2H), 3.81 (dd, 1H, J=2.6, 9.2 Hz), 3.66 (dd, 1H, J=3.7, 9.2 Hz), 2.78 (br, 2H), 2.37 (tt, 1H, J=3.7, 11.5 Hz), 1.97-1.61 (m, 5H), 1.51-1.38 (m, 19H), 1.24-1.13 (m, 1H), 1.10 (s, 9H), 0.95-0.87 (m, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 174.1, 166.5, 165.2, 155.1, 154.6, 80.3, 79.6, 73.8, 62.3, 51.6, 46.5, 43.0, 38.9, 28.5, 28.4, 28.3, 28.2, 27.2, 25.0, 15.1, 11.3. Desired MS 582.38 (M+H). MS Found (MALDI, m/z) 583.08 (M+H).

¹H NMR (300 MHz, CDCl₃) δ 6.80 (d, 1H, J=7.8 Hz), 5.44 (br, 1H), 5.35-5.21 (m, 1H), 4.71 (br, 1H), 4.49 (d, 2H, J=5.9 Hz), 4.07 (br, 2H), 3.14-2.96 (m, 2H), 2.80-2.60 (m, 2H), 2.40-2.24 (m, 1H), 2.01-1.56 (m, 6H), 1.54-1.25 (m, 31H). ¹³C NMR (75 MHz, CDCl₃) δ 174.5, 167.2, 164.5, 156.2, 155.5, 154.6, 80.5, 79.6, 79.2, 77.2, 45.2, 42.9, 39.8, 35.8, 33.0, 29.3, 28.5, 28.4, 28.4, 28.2, 22.2. Desired MS 633.37 (M+H). MS Found (ESI, m/z) 633.19 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 6.91-6.82 (m, 1H), 5.58 (dt, 1H, J=4.9, 8.8 Hz), 5.43 (d, 1H, J=8.8 Hz), 5.06 (br, 1H), 4.10 (br, 2H), 3.80-3.71 (m, 1H), 3.65 (dd, 1H, J=4.1, 9.2 Hz), 2.97 (dt, 1H, J=4.5, 16.5 Hz), 2.82 (ddd, 1H, J=2.6, 5.2, 16.5 Hz), 2.73 (br, 2H), 2.33-2.25 (m, 1H), 1.87-1.76 (m, 2H), 1.68-1.57 (m, 2H), 1.42 (br, 18H), 1.39 (s, 9H), 1.08 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 173.8, 169.6, 166.3, 165.5, 155.1, 154.6, 82.2, 80.4, 79.6, 73.8, 62.3, 48.2, 43.0, 42.2, 37.6, 28.4, 28.4, 28.3, 28.2, 27.9, 27.2. Desired MS 662.38 (M+Na). MS Found (MALDI, m/z) 661.93 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.92-6.81 (m, 4H), 6.15 (d, 1H, J=8.4 Hz), 5.59-5.53 (m, 1H), 5.43 (d, 1H, J=8.4 Hz), 5.11-5.02 (m, 1H), 4.04 (br, 2H), 3.80-3.72 (m, 1H), 3.23 (dd, 1H, J=6.0, 14.1 Hz), 3.09 (dd, 1H, J=6.5, 14.1 Hz), 2.67 (dd, 1H, J=4.1, 9.3 Hz), 2.19 (tt, 1H, J=3.7, 11.5 Hz), 1.75-1.47 (m, 4H), 1.43 (s, 9H), 1.42 (s, 9H), 1.28 (s, 9H), 1.10 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 173.8, 166.3, 165.9, 155.1, 154.6, 154.5, 129.8, 129.6, 124.2, 80.5, 79.6, 78.5, 73.9, 62.4, 48.2, 46.4, 42.9, 38.5, 28.8, 28.6, 28.4, 28.3, 28.1, 27.2. Desired MS 710.42 (M+Na). MS Found (MALDI, m/z) 710.03 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.62 (d, 1H, J=8.0 Hz), 5.46 (d, 1H, J=8.5 Hz), 5.35-5.26 (m, 1H), 5.06 (br, 1H), 4.09 (br, 2H), 3.78-3.70 (br, 1H), 3.65 (dd, 1H, J=4.0, 9.2 Hz), 2.71 (br, 2H), 2.38-2.15 (m, 4H), 2.11-2.01 (m, 1H), 1.83-1.74 (m, 2H), 1.68-1.54 (m, 2H), 1.49-1.31 (m, 27H), 1.07 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.5, 172.3, 166.5, 155.4, 154.9, 81.4, 80.7, 79.8, 74.1, 62.8, 48.5, 45.4, 43.2, 31.4, 28.7, 28.7, 28.6, 28.5, 28.3, 27.5. Desired MS 676.40 (M+Na). MS Found (MALDI, m/z) 676.06 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 7.20 (d, 1H, J=7.6 Hz), 5.59 (d, 1H, J=8.5 Hz), 5.32-5.19 (m, 1H), 4.99 (br, 1H), 4.84 (br, 1H), 4.01 (br, 2H), 3.73-3.55 (m, 2H), 3.05-2.87 (m, 2H), 2.62 (br, 2H), 2.33-2.21 (m, 1H), 1.90-1.50 (m, 6H), 1.49-1.23 (m, 31H), 1.01 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.5, 166.9, 166.0, 156.0, 155.1, 154.4, 80.2, 79.3, 78.8, 73.7, 62.3, 48.1, 44.9, 42.6, 39.8, 33.0, 29.1, 28.5, 28.3, 28.2, 28.1, 28.0, 27.1, 22.1. Desired MS 697.44 (M+H). MS Found (MALDI, m/z) 697.13 (M+H).

¹H NMR (300 MHz, CDCl₃) δ 6.99-6.72 (m, 4H), 5.59-5.50 (m, 2H), 5.28-4.96 (m, 2H), 4.11 (br, 2H), 3.23-2.90 (m, 3H), 2.87-2.88 (m, 3H), 2.35-2.21 (m, 1H), 1.86-1.52 (m, 4H), 1.48-1.32 (m, 27H), 1.29 (s, 9H). ¹³C NMR (75 MHz, CDCl₃) δ 174.0, 169.8, 169.7, 166.9, 166.8, 165.7, 154.6, 129.9, 129.8, 124.2, 82.3, 80.4, 79.6, 78.5, 48.4, 43.0, 42.2, 39.3, 37.6, 28.8, 28.4, 28.4, 28.3, 28.2, 28.0. Desired MS 738.42 (M+Na). MS Found (MALDI, m/z) 738.05 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.97 (d, 2H, J=8.3 Hz), 6.86 (d, 2H, J=8.3 Hz), 6.54-6.41 (br, 1H), 5.30-5.13 (m, 3H), 4.73 (t, 1H, J=5.7 Hz), 4.10 (br, 2H), 3.20-2.98 (m, 4H), 2.71 (br, 2H), 2.34-2.24 (m, 1H), 1.92-1.69 (m, 4H), 1.51-1.20 (m, 40H). ¹³C NMR (125 MHz, CDCl₃) δ 174.4, 166.8, 156.2, 154.8, 154.6, 154.5, 130.1, 129.7, 124.3, 80.4, 79.6, 79.1, 78.5, 48.4, 45.2, 42.9, 39.9, 39.2, 33.1, 29.3, 28.8, 28.6, 28.4, 28.4, 28.3, 28.2, 22.2. Desired MS 795.47 (M+Na). MS Found (MALDI, m/z) 795.18 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.99 (d, 2H, J=8.3 Hz), 6.89 (d, 2H, J=8.3 Hz), 6.52 (d, 1H, J=7.6 Hz), 5.32-5.18 (m, 2H), 5.11 (d, 1H, J=8.4 Hz), 4.13 (br, 2H), 3.19 (dd, 1H, J=6.5, 14.0 Hz), 3.13 (dd, 1H, J=6.6, 14.0 Hz), 2.77 (br, 2H), 2.43-2.16 (m, 4H), 2.14-2.04 (m, 1H), 1.90-1.56 (m, 4H), 1.50-1.34 (m, 27H), 1.32 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.3, 172.2, 166.7, 166.3, 154.7, 154.6, 154.6, 130.0, 129.8, 124.3, 81.3, 80.4, 79.6, 78.5, 48.4, 45.3, 43.0, 39.2, 34.6, 31.2, 28.8, 28.5, 28.4, 28.3, 28.2, 28.0. Desired MS 752.43 (M+Na). MS Found (MALDI, m/z) 752.11 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.96 (d, 2H, J=8.4 Hz), 6.87 (d, 2H, J=8.4 Hz), 6.35 (d, 1H, J=8.3 Hz), 5.38 (dt, 1H, J=3.5, 8.4 Hz), 5.25-5.15 (m, 1H), 5.04 (d, 1H, J=8.3 Hz), 4.12 (br, 2H), 3.79 (dd, 1H, J=2.7, 9.2 Hz), 3.63 (dd, 1H, J=3.6, 9.2 Hz), 3.21-3.04 (m, 2H), 2.76 (t, 2H, J=12.2 Hz), 2.32 (tt, 1H, J=3.7, 11.5 Hz), 1.86-1.76 (m, 2H), 1.71-1.54 (m, 2H), 1.44 (s, 9H), 1.38 (s, 9H), 1.29 (s, 9H), 1.09 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.2, 166.6, 165.4, 154.7, 154.6, 154.5, 130.0, 129.8, 124.2, 80.4, 79.6, 78.5, 73.9, 62.1, 48.3, 46.5, 43.0, 39.2, 28.8, 28.5, 28.4, 28.3, 28.2, 27.3. Desired MS 710.42 (M+Na). MS Found (MALDI, m/z) 710.07 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.61 (t, 1H, J=5.4 Hz), 5.48 (d, 1H, J=8.6 Hz), 5.07-4.99 (m, 1H), 4.62 (d, 2H, J=5.4 Hz), 3.76 (dd, 1H, J=3.2, 9.3 Hz), 3.66 (dd, 1H, J=4.0, 9.3 Hz), 2.71 (br, 2H), 2.32 (tt, 1H, J=3.7, 11.5 Hz), 1.84-1.74 (m, 2H), 1.69-1.57 (m, 2H), 1.41 (s, 18H), 1.07 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.6, 166.4, 163.8, 155.2, 154.6, 80.4, 79.6, 73.9, 62.2, 48.2, 42.8, 34.4, 28.4, 28.2, 27.2. Desired MS 548.32 (M+Na). MS Found (MALDI, m/z) 547.84 (M+Na).

¹H NMR (500 MHz, CDCl₃) δ 6.47 (d, 1H, J=8.5 Hz), 5.49 (d, 1H, J=9.5 Hz), 5.33-5.22 (m, 1H), 4.86 (dd, 1H, J=1.7, 9.5 Hz), 4.70-4.60 (m, 1H), 4.22-3.96 (m, 3H), 3.13-2.98 (m, 2H), 2.70 (br, 2H), 2.29 (tt, 1H, J=3.7, 11.5 Hz), 1.98-1.86 (m, 2H), 1.85-1.71 (m, 2H), 1.69-1.55 (m, 2H), 1.54-1.21 (m, 31H), 1.22 (d, 3H, J=6.2 Hz), 0.92 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.2, 166.6, 166.5, 156.1, 155.7, 154.6, 80.3, 79.6, 79.1, 74.4, 68.1, 53.3, 45.1, 42.9, 39.9, 33.2, 29.3, 28.7, 28.5, 28.4, 28.4, 28.3, 28.0, 22.3, 20.1. Desired MS 711.46 (M+H). MS Found (MALDI, m/z) 711.03 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 6.65 (d, 1H, J=7.2 Hz), 5.36 (d, 1H, J=7.8 Hz), 5.30-5.21 (m, 1H), 4.93 (br, 1H), 4.69 (br, 1H), 4.08 (br, 2H), 3.13-2.99 (m, 2H), 2.70 (br, 2H), 2.32 (tt, 1H, J=3.7, 11.5 Hz), 1.99-1.70 (m, 5H), 1.69-1.55 (m, 2H), 1.54-1.29 (m, 32H), 1.19-1.07 (m, 1H), 0.91-0.80 (m, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 174.3, 167.2, 166.3, 156.1, 155.1, 154.6, 80.3, 79.6, 79.1, 49.7, 47.0, 42.9, 39.9, 38.7, 33.1, 29.4, 28.7, 28.4, 28.3, 28.2, 28.1, 25.0, 22.3, 15.1, 11.3. Desired MS 667.43 (M+H). MS Found (MALDI, m/z) 667.04 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 6.91 (d, 1H, J=8.8 Hz), 5.55 (dt, 1H, J=5.0, 8.8 Hz), 4.16-3.92 (m, 3H), 3.80-3.66 (m, 2H), 2.96 (ddd, 1H, J=1.5, 4.7, 16.6 Hz), 2.83 (dd, 1H, J=5.1, 16.6 Hz), 2.71 (br, 2H), 2.28 (tt, 1H, J=3.7, 11.5 Hz), 2.23 (s, 6H), 1.84-1.72 (m, 2H), 1.66-1.54 (m, 2H), 1.45-1.28 (m, 18H), 1.09 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 173.9, 169.6, 165.4, 165.0, 154.5, 82.1, 79.5, 73.4, 61.2, 61.0, 60.8, 42.9, 42.3, 42.3, 42.1, 37.7, 28.3, 27.9, 27.2. Desired MS 568.36 (M+H). MS Found (MALDI, m/z) 568.04 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 6.74 (br, 1H), 5.32 (dt, 1H, J=4.9, 8.2 Hz), 4.20-3.90 (m, 3H), 3.82-3.67 (m, 2H), 2.70 (br, 2H), 2.37-2.15 (m, 10H), 2.13-2.01 (m, 1H), 1.78 (br, 2H), 1.67-1.54 (m, 2H), 1.42-1.35 (m, 18H), 1.09 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 174.2, 172.0, 166.2, 165.1, 154.5, 81.1, 79.5, 73.4, 61.2, 60.9, 45.3, 42.9, 42.2, 42.2, 31.1, 28.4, 28.3, 28.2, 28.0, 27.3. Desired MS 582.38 (M+H). MS Found (MALDI, m/z) 581.97 (M+H).

¹H NMR (500 MHz, CDCl₃) δ 6.96-6.75 (m, 4H), 6.36 (br, 1H), 5.65-5.51 (m, 1H), 4.20-3.88 (m, 3H), 3.86-3.66 (m, 2H), 3.21 (dd, 1H, J=5.8, 13.6 Hz), 3.08 (dd, 1H, J=5.7, 13.6 Hz), 2.66 (br, 2H), 2.30-2.16 (m, 7H), 1.75-1.61 (m, 2H), 1.60-1.46 (m, 2H), 1.40 (s, 9H), 1.26 (s, 9H), 1.12 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 173.8, 166.0, 165.1, 154.6, 154.5, 129.8, 129.5, 124.1, 79.5, 78.4, 73.5, 61.2, 61.0, 60.9, 46.5, 42.8, 42.2, 38.7, 38.6, 28.7, 28.3, 27.3. Desired MS 616.40 (M+H). MS Found (MALDI, m/z) 616.05 (M+H).

The following general method may be used to prepare protected monovalent compounds h″ through w″ and l′″ through y′″ (Scheme 11). Synthesis of protected monovalent compound o″ is demonstrated in Scheme 12 as a representative example.

The following general method may be used to prepare protected monovalent compounds x″ through k′″ (Scheme 13). Synthesis of protected monovalent compound i′″ is demonstrated in Scheme 14 as a representative example.

Characterization data for protected monovalent compounds h″ through y′″ follows:

¹H NMR (500 MHz, CDCl₃) δ 7.38 (s, 1H), 6.78-6.91 (m, 2H), 6.50-6.68 (m, 2H), 5.16-5.36 (m, 1H), 4.99 (s, 1H), 3.33-3.92 (m, 6H), 2.90-3.33 (m, 4H), 2.16-2.40 (m, 1H), 1.46 (s, 9H), 1.41 (s, 9H), 1.18-1.33 (m, 1H), 0.94 (t, J=6.6 Hz, 3H), 0.84-0.91 (m, 2H), 0.80 (d, J=6.3 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.4, 154.8, 152.7, 148.1, 130.6, 130.4, 128.6, 120.1, 115.3, 80.8, 79.8, 63.6, 48.6, 42.2, 40.5, 29.7, 28.4, 28.3, 24.3, 15.8, 10.4. MS (ESI) for C₃₀H₄₇N₆O₆ [M+H]⁺ calcd 587.73, found 587.33.

¹H NMR (500 MHz, CDCl₃) δ 7.75 (s, 1H), 5.38 (d, J=10.5 Hz, 1H), 4.94-5.03 (m, 1H), 4.82-4.92 (m, 1H), 3.66-3.78 (m, 2H), 3.55-3.66 (b, 1H), 3.43-3.55 (m, 3H), 3.20-3.32 (b, 1H), 3.00-3.22 (b, 1H), 2.32-2.42 (m, 1H), 1.74 (t, J=7.5 Hz, 2H), 1.52-1.66 (m, 1H), 1.46 (s, 9H), 1.41 (s, 9H), 0.90-1.06 (m, 2H), 1.00 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 6H), 0.82 (t, J=7.5 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.8, 155.5, 154.6, 150.0, 120.1, 80.8, 79.7, 63.7, 46.3, 45.6, 44.5, 42.5, 38.1, 28.6, 25.0, 24.7, 23.0, 22.5, 16.0, 10.7. MS (ESI) for C₂₇H₄₉N₆O₅ [M+H]⁺ calcd 537.38, found 537.38.

¹H NMR (500 MHz, CDCl₃) δ 8.39 (s, 1H), 7.95 (s, 1H), 7.60 (d, J=8 Hz, 1H), 7.37 (d, J=8 Hz, 1H), 7.21-7.24 (m, 1H), 7.15-7.18 (m, 1H), 6.99 (d, J=2 Hz, 1H), 6.02 (t, J=5 Hz, 1H), 5.07 (d, J=8 Hz, 1H), 4.93 (d, J=8 Hz, 1H), 3.70 (dd, J=4.5, 9 Hz, 1H), 3.48-3.56 (m, 1H), 3.26-3.44 (m, 4H), 3.06-3.14 (b, 1H), 2.82-3.06 (b, 1H), 2.36-2.58 (b, 1H), 1.88-2.05 (b, 1H), 1.76 (t, J=7.5 Hz, 2H), 1.62 (m, 1H), 1.45 (s, 9H), 1.41 (s, 9H), 0.96 (d, J=6.5 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 167.0, 155.5, 154.5, 149.8, 136.3, 127.1, 123.6, 122.8, 120.6, 120.3, 118.5, 111.8, 109.3, 80.6, 79.7, 59.4, 46.0, 45.6, 44.9, 42.4, 30.3, 28.6, 28.5, 25.0, 22.9, 22.5. MS (ESI) for C₃₂H₄₈N₇O₅ [M+H]⁺ calcd 610.37, found 610.37.

¹H NMR (500 MHz, CDCl₃) δ 7.70 (s, 1H), 5.65 (t, J=8 Hz, 1H), 5.05-5.15 (m, 1H), 4.82-4.97 (m, 1H), 4.56 (s, 1H), 3.68-3.80 (b, 1H), 3.61-3.68 (m, 1H), 3.38-3.60 (m, 4H), 3.20-3.32 (b, 1H), 2.98-3.19 (m, 3H), 2.15-2.24 (m, 1H), 1.86-2.10 (m, 2H), 1.76 (t, J=7.5 Hz, 2H), 1.54-1.68 (m, 1H), 1.46 (s, 9H), 1.44 (s, 9H), 1.43 (s, 9H), 1.22-1.35 (m, 1H), 1.16-1.22 (m, 1H), 0.94 (d, J=6.5 Hz, 6H)¹³C NMR (125 MHz, CDCl₃) δ 166.5, 156.3, 155.5, 154.6, 150.0, 120.1, 80.8, 79.7, 79.5, 59.7, 46.0, 45.6, 42.6, 40.0, 32.7, 29.7, 28.7, 28.6, 28.5, 25.1, 22.9, 22.8, 22.5. MS (ESI) for C₃₂H₅₈N₇O₇ [M+H]⁺ calcd 652.44, found 652.44.

¹H NMR (500 MHz, CDCl₃) δ 7.75 (s, 1H), 5.80-5.95 (m, 1H), 5.05 (d, J=8 Hz, 1H), 4.80-4.95 (m, 1H), 3.59-3.74 (b, 3H), 3.42-3.58 (m, 3H), 3.27-3.35 (m, 1H), 3.10-3.27 (b, 1H), 2.30-2.40 (m, 1H), 2.05-2.28 (m, 2H), 1.93-2.07 (m, 1H), 1.75 (t, J=7.5 Hz, 2H), 1.52-1.68 (m, 1H), 1.46 (s, 9H), 1.44 (s, 9H), 1.42 (s, 9H), 0.93 (d, J=7 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 171.7, 166.6, 155.5, 154.6, 150.0, 120.4, 81.5, 80.7, 79.7, 58.7, 45.9, 45.6, 44.8, 42.5, 30.4, 28.6, 28.6, 28.3, 25.0, 22.9, 22.5. MS (ESI) for C₃₂H₅₃N₆O₇ [M+H]⁺ calcd 609.40, found 609.40.

¹H NMR (500 MHz, CDCl₃) δ 7.85 (s, 1H), 6.99 (d, J=8.5 Hz, 2H), 6.76 (d, J=8 Hz, 2H), 5.80-5.90 (b, 1H), 5.09 (d, J=8.5 Hz, 1H), 4.90 (d, J=6.5 Hz, 1H), 3.46-3.62 (b, 2H), 3.18-3.46 (m, 5H), 3.02-3.18 (m, 2H), 2.86-3.00 (b, 1H), 1.68-1.82 (m, 2H), 1.52-1.68 (m, 1H), 1.45 (s, 9H), 1.44 (s, 9H), 0.94 (d, J=6.5 Hz, 6H). ¹³C NMR (125 MHz, CDCl₃) δ 166.4, 156.1, 154.5, 149.8, 130.7, 125.9, 120.7, 116.1, 80.9, 79.9, 60.4, 46.0, 45.5, 44.7, 42.5, 39.3, 28.6, 28.5, 25.0, 22.9, 22.5. MS (ESI) for C₃₀H₄₇N₆O₆ [M+H]⁺ calcd 587.36, found 587.35.

¹H NMR (500 MHz, CDCl₃) δ 8.77 (s, 1H), 7.86 (s, 1H), 7.56 (d, J=7.8 Hz, 1H), 7.32 (d, J=8.1 Hz, 1H), 7.09-7.30 (m, 2H), 6.94 (s, 1H), 5.95-6.05 (b, 1H), 5.42 (d, J=8.4 Hz, 1H), 4.77 (t, J=7.2 Hz, 1H), 3.61-3.78 (m, 2H), 3.08-3.59 (m, 5H), 2.72-3.09 (m, 3H), 2.20-2.60 (b, 1H), 1.84-2.04 (b, 1H), 1.42 (s, 9H), 1.38 (s, 9H), 0.99-1.25 (m, 2H), 0.84-0.99 (m, 3H), 0.75-0.83 (m, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.6, 155.4, 154.1, 147.4, 136.0, 126.8, 123.4, 122.4, 120.7, 119.8, 118.1, 111.5, 108.7, 80.3, 79.4, 59.1, 51.5, 45.6, 42.0, 39.3, 30.0, 28.3, 28.2, 25.2, 15.1, 11.4. MS (ESI) for C₃₂H₄₇N₇O₅ [M+H]⁺ calcd 610.37, found 610.35.

¹H NMR (500 MHz, CDCl₃) δ 7.57 (s, 1H), 5.55-5.60 (m, 1H), 5.32 (d, J=8.7 Hz, 1H), 4.67-4.70 (m, 1H), 4.48-4.60 (b, 1H), 3.26-3.78 (m, 7H), 2.83-3.25 (m, 4H), 1.78-2.20 (m, 4H), 1.38 (s, 18H), 1.36 (s, 9H), 1.12-1.28 (m, 2H), 0.92-1.12 (m, 2H), 0.84 (t, J=7.2 Hz, 3H), 0.74 (d, J=6.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.2, 156.0, 155.4, 154.3, 147.9, 120.0, 80.5, 79.4, 79.2, 59.3, 51.5, 45.6, 42.3, 39.7, 39.3, 32.4, 29.4, 28.3, 28.3, 28.2, 25.3, 22.5, 15.1, 11.5. MS (ESI) for C₃₂H₅₈N₇O₇ [M+H]⁺ calcd 652.44, found 652.45.

¹H NMR (500 MHz, CDCl₃) δ 7.63 (s, 1H), 5.78-5.90 (b, 1H), 5.37 (d, J=8.4 Hz, 1H), 4.59-4.73 (b, 1H), 3.54-3.78 (b, 3H), 3.32-3.53 (m, 3H), 3.00-3.32 (m, 2H), 2.23-2.40 (m, 1H), 2.04-2.22 (m, 3H), 1.75-2.04 (m, 2H), 1.40 (s, 9H), 1.38 (s, 9H), 1.37 (s, 9H), 0.93-1.13 (m, 1H), 0.85 (t, J=7.2 Hz, 3H), 0.75 (d, J=6.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 171.4, 166.1, 155.3, 154.2, 147.5, 120.4, 81.1, 80.3, 79.2, 58.3, 51.4, 45.5, 43.3, 42.2, 39.2, 30.0, 28.2, 28.1, 27.9, 25.2, 15.0, 11.4. MS (ESI) for C₃₀H₅₃N₅O₇ [M+H]⁺ calcd 609.40, found 609.39.

¹H NMR (500 MHz, CDCl₃) δ 7.75 (s, 1H), 6.92 (d, J=7.8 Hz, 2H), 6.72 (d, J=8.1 Hz, 2H), 5.75-5.87 (b, 1H), 5.37 (d, J=8.7 Hz, 1H), 4.71 (t, J=7.5 Hz, 1H), 3.42-3.59 (b, 2H), 2.98-3.42 (m, 7H), 2.78-2.98 (b, 1H), 1.78-2.00 (b, 2H), 1.40 (s, 9H), 1.39 (s, 9H), 0.97-1.16 (m, 2H), 0.87 (t, J=7.2 Hz, 3H), 0.77 (d, J=6.6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.1, 156.0, 155.6, 154.3, 147.9, 130.3, 125.9, 120.9, 115.9, 80.6, 79.6, 60.1, 51.5, 45.7, 42.2, 39.2, 30.9, 28.3, 28.2, 25.2, 15.2, 11.4. MS (ESI) for C₃₀H₄₇N₆O₆ [M+H]⁺ calcd 587.36, found 587.32.

¹H NMR (500 MHz, CDCl₃) δ 10.58 (s, 1H), 8.18 (s, 1H), 7.57 (d, J=8 Hz, 1H), 7.37 (d, J=8.5 Hz, 1H), 7.11-7.18 (m, 2H), 7.07 (t, J=7 Hz, 2H), 6.14 (dd, J=3.5, 10 Hz, 1H), 3.71-3.87 (m, 3H), 3.48-3.63 (m, 2H), 3.13-3.36 (m, 7H), 3.05-3.13 (m, 1H), 2.58-2.68 (m, 1H), 2.04-2.20 (b, 1H), 1.46 (s, 9H), 1.41 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 166.9, 155.9, 154.5, 147.4, 136.1, 127.1, 123.5, 122.8, 121.94, 120.3, 118.3, 111.8, 109.0, 80.7, 80.2, 65.2, 59.6, 48.6, 46.0, 42.4, 30.2, 28.6, 28.5. MS (ESI) for C₂₉H₄₂N₇O₆ [M+H]⁺ calcd 584.32, found 584.32.

¹H NMR (500 MHz, CDCl₃) δ 7.86 (s, 1H), 5.45-5.81 (m, 2H), 4.92 (s, 1H), 4.60 (s, 1H), 4.12 (s, 1H), 3.91 (s, 1H), 3.41-3.80 (m, 6H), 2.93-3.41 (m, 5H), 2.37-2.86 (b, 2H), 2.18 (s, 1H), 2.05 (s, 1H), 1.46 (s, 9H), 1.44 (s, 9H), 1.43 (s, 9H), 1.08-1.37 (m, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 166.5, 156.3, 155.9, 154.6, 147.7, 121.5, 80.8, 80.2, 79.5, 65.3, 59.8, 48.7, 46.1, 42.6, 40.0, 32.7, 29.6, 28.7, 28.6, 28.5, 22.8. MS (ESI) for C₂₉H₅₂N₇O₈ [M+H]⁺ calcd 626.39, found 626.38.

¹H NMR (500 MHz, CDCl₃) δ 7.88 (s, 1H), 5.90 (q, J=4.5 Hz, 1H), 5.48-5.69 (m, 1H), 4.92 (s, 1H), 4.01-4.18 (m, 1H), 3.85-3.96 (m, 1H), 3.59-3.78 (b, 3H), 3.41-3.59 (m, 3H), 3.21-3.41 (m, 2H), 2.56-3.16 (b, 1H), 2.30-2.43 (m, 1H), 2.16-2.29 (m, 2H), 1.96-2.10 (m, 1H), 1.46 (s, 9H), 1.44 (s, 18H). ¹³C NMR (125 MHz, CDCl₃) δ 171.7, 166.5, 155.9, 154.6, 147.6, 121.7, 155.9, 154.6, 147.6, 81.6, 80.8, 80.2, 65.3, 58.8, 45.9, 42.6, 30.4, 28.6, 28.3. MS (ESI) for C₂₇H₄₇N₆O₈ [M+H]⁺ calcd 583.35, found 583.31.

¹H NMR (500 MHz, CDCl₃) δ 7.96 (s, 1H), 5.23-5.78 (m, 2H), 4.78-5.05 (b, 1H), 4.0-4.26 (m, 1H), 3.80-4.00 (m, 1H), 3.60-3.78 (b, 3H), 3.40-3.60 (m, 3H), 3.19-3.40 (m, 1H), 3.13-3.19 (b, 1H), 2.44-2.86 (b, 2H), 1.46 (s, 9H), 1.44 (s, 9H), 0.89-1.35 (m, 5H), 0.83 (q, J=6 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 166.8, 155.9, 154.6, 147.7, 121.5, 80.8, 80.2, 65.3, 63.6, 48.6, 46.4, 42.5, 38.2, 28.6, 28.5, 24.8, 15.9, 10.7. MS (ESI) for C₂₄H₄₃N₆O₆ [M+H]⁺ calcd 511.33, found 511.32.

¹H NMR (500 MHz, CDCl₃) δ 7.35 (s, 1H), 6.78-6.92 (m, 2H), 6.56-6.72 (m, 2H), 5.72-5.85 (b, 1H), 5.24-5.44 (m, 1H), 4.90-5.08 (m, 1H), 3.31-3.78 (b, 7H), 3.09-3.26 (m, 2H), 2.84-3.09 (m, 2H), 2.21-2.40 (m, 1H), 2.02-2.20 (m, 2H), 1.45 (s, 9H), 1.41 (s, 9H), 1.39 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 171.6, 166.1, 155.1, 154.4, 148.1, 130.5, 128.3, 120.3, 115.3, 81.4, 80.7, 79.7, 58.3, 48.6, 48.5, 45.3, 42.1, 41.0, 40.7, 30.1, 28.3, 28.0, 27.9. MS (ESI) for C₃₃H₅₁N₆O₈ [M+H]⁺ calcd 659.38, found 659.34.

¹H NMR (500 MHz, CDCl₃) δ 8.57 (s, 1H), 7.40-7.62 (m, 2H), 7.27-7.36 (m, 1H), 7.03-7.21 (m, 2H), 6.80-6.94 (m, 2H), 6.77 (s, 1H), 6.3 (d, J=8.4 Hz, 2H), 5.77-5.97 (b, 1H), 5.24-5.46 (m, 1H), 4.96-5.12 (m, 1H), 2.81-3.68 (m, 12H), 1.42 (s, 9H), 1.41 (s, 9H). ¹³C NMR (125 MHz, CDCl₃) δ 166.2, 155.2, 154.9, 148.0, 137.9, 136.0, 130.5, 128.6, 126.8, 123.5, 122.4, 120.3, 119.9, 118.0, 111.5, 108.8, 80.8, 79.8, 59.4, 48.6, 45.4, 42.1, 40.6, 29.5, 28.3. MS (ESI) for C₃₅H₄₆N₇O₆ [M+H]⁺ calcd 660.35, found 660.34.

¹H NMR (CDCl₃) δ 7.57 (s, 1H), 6.31 (s, 1H), 5.01 (s, 1H), 4.14 (m, 1H), 3.56 (t, 2H, J=4.5, J=5.7), 3.44 (s, 4H), 3.40 (t, 2H, J=5.7, J=4.8), 3.23 (q, 2H, J=6.6, J=6.3, J=6.9), 2.95 (s, 1H), 2.91 (dd, 1H, J=3.9, J=11.1, J=3.6), 2.80 (dd, 1H, J=7.1, J=6.9, J=8.1), 2.32 (t, 2H, J=7.5, J=7.8), 1.62 (m, 2H), 1.47 (s, 11H), 1.29-1.21 (m, 15H); HRMS (ESI, m/z): (M+H)⁺ calcd for C₂₇H₄₉N₆O₅ 537.3759, found 537.3538.

¹H NMR (CDCl₃) δ 7.69 (s, 1H), 7.06 (t, 1H, J=5.4, J=5.7), 5.28 (t, 1H, J=5.1, J=5.7), 4.37 (t, 1H, J=6, J=6.3), 4.39-4.08 (m, 2H), 3.53 (t, 2H, J=4.5, J=5.7), 3.40 (s, 4H), 3.35 (t, 2H, J=5.7, J=4.8), 3.18 (q, 2H, J=6.6, J=7.2, J=6.3), 2.77 (t, 2H, J=7.5, J=7.8), 2.50 (t, 1H, J=6.9, J=7.5), 2.27 (t, 2H, J=7.5, J=7.8), 2.06 (s, 3H), 1.93 (p, 2H, J=7.5, J=7.5, J=7.2, J=7.2), 1.56 (m, 2H), 1.42 (s, 11H), 1.24 (br, 4H), 1.78 (br, 8H); ¹³C NMR (CDCl₃) δ 172.2, 167.12, 154.8, 147.6, 122.0, 80.5, 77.0, 65.1, 63.0, 45.7, 41.6, 40.0, 33.8, 33.6, 29.6, 29.5, 29.4, 29.3, 29.3, 28.7, 28.6, 26.9, 25.4, 24.7, 15.6; HRMS (ESI, m/z): (M+H)⁺ calcd for C₂₉H₅₃N₆O₅S 597.3793, found 597.3770.

¹H NMR (CDCl₃) δ 7.60 (s, 1H), 6.79 (t, 1H, J=5.4, J=5.4), 5.11 (t, 1H, J=7.8, J=6.9), 4.75 (s, 1H), 3.59 (t, 2H, J=4.5, J=5.7), 3.45 (s, 4H), 3.40 (t, 2H, J=6.0, J=4.5), 3.20 (q, 2H, J=6.6, J=7.2, J=6.3), 3.07 (m, 2H), 2.18 (t, 2H, J=7.2, J=7.2), 2.40 (br, 2H), 2.34 (t, 2H, J=7.5, J=7.8), 2.21-2.15 (br, 2H), 2.03 (p, 2H, J=7.2, J=6.9, J=6.9, J=7.2), 1.60 (m, 2H), 1.55-1.46 (m, 11H), 1.42 (s, 9H), 1.28-1.25 (m, 4H), 1.22 (br, 12H); ¹³C NMR (CDCl₃) δ 176.16, 172.55, 168.39, 156.46, 154.86, 147.40, 121.53, 80.64, 79.51, 64.45, 45.71, 41.63, 40.22, 40.04, 33.56, 33.51, 33.79, 29.57, 29.51, 29.32, 28.64, 28.60, 26.95, 25.51, 25.04, 24.52, 23.06; HRMS (ESI, m/z): (M+H)⁺ calcd for C₃₇H₆₆N₇O₈ 736.4967, found 736.4785.

¹H NMR (CDCl₃) δ 7.54 (s, 1H), 6.74 (s, 1H), 5.09 (q, 1H, J=6.0, J=3.6, J=5.7), 4.66 (s, 1H), 3.60 (t, 2H, J=4.8, J=5.4), 3.45 (s, 4H), 3.41 (t, 2H, J=5.4, J=5.1), 3.21 (q, 2H, J=6.6, J=6.9, J=6.6), 3.06 (m, 2H), 2.37 (s, 3H), 2.33 (t, 2H, J=9.9, J=7.8), 2.29-2.05 (m, 2H), 1.62 (m, 2H), 1.51 (m, 2H), 1.48 (s, 9H), 1.44 (s, 9H), 1.30 (br, 6H), 1.23 (br, 10H); HRMS (ESI, m/z): (M+H)⁺ calcd for C₃₄H₆₂N₇O₆ 664.4756, found 664.24.

¹H NMR (CDCl₃) δ 7.70 (s, 1H), 7.27 (s, 1H), 5.15 (t, 1H, J=8.7, J=6.6), 4.88 (s, 1H), 3.85 (t, 2H, J=6, J=6.3), 3.53 (t, 2H, J=4.5, J=5.7), 3.39 (s, 4H), 3.34 (t, 2H, J=5.4, J=4.8), 3.14 (m, 2H), 2.998 (q, 2H, J=6.3, J=6.6, J=6.9), 2.90 (t, 2H, J=6.0, J=6.3), 2.28 (t, 2H, J=7.2, J=8.1), 2.16-2.02 (m, 2H), 1.53 (m, 2H), 1.42 (m, 11H), 1.37 (s, 9H), 1.23 (br, 4H), 1.18 (br, 12H); HRMS (ESI, m/z): (M+H)⁺ calcd for C₃₅H₆₄N₇O₇ 694.4862, found 694.4270.

¹H NMR (CDCl₃) δ 7.48 (s, 1H), 6.69 (s, 1H), 5.06 (q, 1H, J=6.0, J=3.3, J=6.0), 4.62 (s, 1H), 3.58 (t, 2H, J=4.5, J=5.4), 3.43 (s, 4H), 3.39 (t, 2H, J=5.4, J=4.8), 3.19 (q, 2H, J=6.3, J=7.2, J=6.3), 3.05 (m 2H), 2.71 (dd, 11H, J=5.7, J=8.7, J=6.0), 2.51 (dd, 1H, J=8.1, J=6.6, J=7.8), 2.32 (t, 2H, J=7.2, J=8.1), 2.370-2.10 (m, 2H), 1.73 (m, 2H), 1.50 (m, 2H), 1.46 (s, 9H), 1.42 (s, 2H), 1.37 (m, 2H), 1.33-1.26 (br, 6H), 1.26-1.12 (br, 10H), 2.90 (t, 3H, J=7.2, J=6.6), 0.87 (d, 3H, J=6.6); HRMS (ESI, m/z): (M+H)⁺ calcd for C₃₈H₇₀N₇O₆ 720.5382, found 720.5566.

¹H NMR (CDCl₃) δ 11.43 (s, 1H), 8.40 (t, 1H, J=5.5, J=5.7), 7.58 (s, 1H), 6.83 (t, 1H, J=5.4, J=6.0), 5.29 (q, 1H, J=6.3, J=3.3, J=5.7), 3.46 (m, 2H), 3.43 (s, 4H), 3.39 (m, 2H), 3.25-4.14 (m, 2H), 2.71 (dd, 1H, J=6.3, J=8.4, J=5.7), 2.51 (dd, 1H, J=8.1, J=6.3, J=7.8), 2.31 (t, 2H, J=7.5, J=7.8), 2.33-2.10 (m, 2H), 1.73 (m, 1H), 1.60 (m, 2H), 1.49 (s, 22H), 1.46 (s, 9H), 1.27 (br, 4H), 1.22 (br, 10H), 0.89 (t, 3H, J=7.5, J=5.1), 0.87 (d, 3H, J=6.6); ¹³C NMR (CDCl₃) δ 171.80, 167.98, 162.46, 156.12, 154.46, 153.00, 147.27, 121.14, 83.51, 80.16, 63.14, 45.30, 41.19, 39.66, 39.43, 34.78, 33.26, 32.57, 30.10, 29.29, 29.25, 29.21, 29.12, 29.00, 28.25, 28.13, 27.92, 26.82, 25.32, 25.15, 18.28, 11.29; HRMS (ESI, m/z): (M+H)⁺ calcd for C₄₃H₇₈N₉O₈ 848.5968, found 848.7464.

¹H NMR (500 MHz, DMSO-d₆): δ=8.46 (t, J=5.5 Hz, 1H), 7.94 (s, 1H), 5.30 (m, 1H), 4.69 (t, J=, 1H), 3.64 (dd, 2H), 3.41-3.34 (m, 10H), 3.10-3.00 (m, 2H), 2.76 (t, J=, 2H), 2.29-2.26 (m, 6H), 2.03 (s, 3H), 1.40 (m, 11H), 1.22 (m, J=, 12H); ¹³C NMR (126 MHz, DMSO-d₆): δ=171.48, 167.85, 154.46, 145.06, 122.06, 79.78, 62.23, 60.97, 55.60, 41.39, 40.68, 39.38, 32.98, 32.25, 29.91, 29.64, 29.59 29.57, 29.47, 29.36, 29.32, 28.70, 15.06. TOF MS calcd for C₂₉H₅₂N₆O₅S 596.83; found: 597.55.

¹H NMR (500 MHz, DMSO-d₆): δ=8.49 (t, J=5.5 Hz, 1H), 7.85 (s, 1H), 5.13 (d, J=6 Hz, 1H), 5.012 (d, J=6 Hz, 1H), 4.23 (m, 1H), 3.40-3.26 (m, 10H), 3.11-2.98 (m, 2H), 2.29 (t, J=7.5 Hz, 2H), 2.22 (s, 3H), 1.47 (m, 14H), 1.24 (m, 12H), 1.06 (d, J=6 Hz, 3H); ¹³C NMR (126 MHz, DMSO-d₆): δ=171.46, 167.22, 154.45, 141.89, 122.34, 79.76, 69.77, 67.09, 45.31, 41.38, 39.26, 32.97, 29.61, 29.58, 29.56, 29.47, 29.34, 29.31, 28.69, 26.96, 25.42, 20.94, 11.26. TOF MS calcd for C₂₇H₄₈N₆O₅ 536.71; found: 537.49.

¹H NMR (500 MHz, DMSO-d₆): δ=8.26 (t, J=5.5 Hz, 1H), 7.76 (s, 1H), 6.79 (t, J=6 Hz, 1H), 4.98 (s, 2H), 3.41-3.25 (m, 10H), 3.08 (q, J=7.5 Hz, 2H), 2.90 (q, J=6.5 Hz, 2H), 2.60 (t, J=7.5, 2H), 2.29 (t, J=7.5, 2H), 1.40-1.36 (m, 30H), 1.24 (m, 16H); ¹³C NMR (126 MHz, DMSO-d₆): δ=171.46, 165.94, 156.22, 154.45, 147.19, 123.88, 79.76, 77.94, 55.60, 52.19, 45.31, 41.38, 39.39, 32.97, 29.92, 29.65, 29.62, 29.58, 29.47, 29.40, 29.37, 28.94, 28.69, 27.03, 26.58, 25.64, 25.42. TOF MS calcd for C₃₄H₆₁N₇O₆ 663.89; found: 664.49.

¹H NMR (500 MHz, DMSO-d₆): δ=8.40 (t, J=5.5 Hz, 1H), 7.86 (s, 1H), 6.79 (t, J=6 Hz, 1H), 5.28-5.22 (m, 2H), 3.92 (t, J=6 Hz, 2H), 3.41-3.25 (m, 10H), 3.06 (q, J=7.5 Hz, 2H), 2.97 (q, J=7.5 Hz, 2H), 2.60 (t, J=6 Hz, 2H), 2.29 (t, J=6 Hz, 2H), 1.59 (m, 2H), 1.40 (m, 28H), 1.24 (m, 16H); ¹³C NMR (126 MHz, DMSO-d₆): δ=171.47, 166.86, 156.22, 154.45, 147.04, 121.73, 79.76, 77.95, 65.45, 62.06, 45.31, 41.39, 39.36, 32.97, 29.92, 29.63, 29.60, 29.58, 29.47, 29.42, 29.34, 28.94, 28.69, 26.92, 26.67, 25.77, 25.43. TOF MS calcd for C₃₅H₆₃N₇O₇ 693.92; found: 694.51.

¹H NMR (500 MHz, DMSO-d₆): δ=8.55 (t, J=5.5 Hz, 1H), 7.88 (s, 1H), 6.77 (t, J=6 Hz, 1H), 4.95 (d, J=11 Hz, 1H), 3.41-3.25 (m, 8H), 3.15-2.95 (m, 2H), 2.89 (q, J=7.5 Hz, 2H), 2.59 (t, J=6 Hz, 2H), 2.29 (t, J=6 Hz, 2H), 2.20 (m, 1H), 1.58 (m, 2H), 1.39 (m, 24H), 1.26 (m, 15H), 0.90 (d, J=6.5 Hz, 3H), 0.75 (t, J=7 Hz, 3H); ¹³C NMR (126 MHz, DMSO-d₆): δ=171.45, 168.07, 156.21, 154.44, 147.57, 120.94, 95.00, 79.75, 77.92, 67.75, 45.31, 41.38, 39.18, 37.17, 32.97, 29.85, 29.62, 29.56, 29.46, 29.32, 29.28, 28.93, 28.68, 26.94, 26.60, 25.73, 25.42, 24.96, 15.65, 10.53. TOF MS calcd for C₃₈H₆₉N₇O₈ 720.00; found: 720.58.

¹H NMR (500 MHz, DMSO-d₆): δ=11.50 (s, 1H), 8.54 (t, J=5.5 Hz, 1H), 8.30 (t, J=5.5 Hz, 1H), 7.90 (s, 1H), 4.96 (d, J=11 Hz, 1H), 3.40-3.25 (m, 10H), 3.16 (m, 1H), 3.10 (m, 1H), 2.64 (t, J=6 Hz, 2H), 2.29 (t, J=6 Hz, 2H), 2.19 (m, 1H), 1.60 (m, 2H), 1.51 (m, 15H), 1.39 (m, 22H), 1.20 (m, 12H), 0.95 (d, J=6.5 Hz, 3H), 0.75 (t, J=7 Hz, 3H); ¹³C NMR (126 MHz, DMSO-d₆): δ=171.44, 168.04, 163.81, 155.89, 154.44, 152.76, 147.36, 121.05, 83.50, 79.75, 78.72, 67.75, 55.59, 45.31, 41.38, 39.17, 37.20, 32.97, 29.61, 29.55, 29.46, 29.32, 29.26, 28.83, 28.68, 28.65, 28.27, 26.92, 25.41, 25.35, 24.96, 15.65, 10.52. TOF MS calcd for C₄₃H₇₇N₉O₈ 848.13; found: 848.57.

¹H NMR (500 MHz, DMSO-d₆): δ=8.42 (t, J=5.5 Hz, 1H), 7.88 (s, 1H), 6.78 (t, J=6 Hz, 1H), 5.19 (t, J=8 Hz, 1H), 3.40-3.25 (m, 8H), 3.11-2.99 (m, 2H), 2.90 (q, J=6.5 Hz, 2H), 2.59 (t, J=6 Hz, 2H), 2.29-2.04 (m, 6H), 1.58 (m, 2H), 1.39 (m, 37H), 1.21 (m, 14H); ¹³C NMR (126 MHz, DMSO-d₆): δ=171.52, 171.45, 167.82, 156.20, 154.44, 147.55, 121.35, 80.69, 79.75, 77.92, 62.48, 45.31, 41.38, 39.31, 32.97, 31.51, 29.88, 29.67, 29.60, 29.58, 29.46, 29.33, 29.27, 28.93, 28.68, 28.36, 28.00, 26.91, 26.62, 25.73, 25.42. TOF MS calcd for C₄₁H₇₃N₇O₈ 792.06; found: 792.64.

¹³C NMR (75 MHz, CDCl₃) δ: 166.6, 156.4, 156.1, 154.6, 146.3, 121.0, 80.8, 80.0, 79.5, 59.7, 46.0, 42.6, 40.0, 36.6, 32.7, 29.7, 28.7, 28.6, 22.9. MS (MALDI) calculated [M+H]: 596.37, found: 596.03.

¹³C NMR (75 MHz, CDCl₃) δ: 166.2, 163.6, 156.5, 155.6, 154.5, 153.4, 120.2, 83.5, 80.6, 79.6, 58.9, 51.8, 45.9, 43.6, 42.6, 39.6, 30.0, 28.5, 25.2, 25.4, 15.4, 11.7. MS (MALDI) calculated [M+H]: 780.49, found: 780.30.

¹³C NMR (75 MHz, CDCl₃) δ: 171.2, 166.1, 155.9, 155.2, 154.1, 149.3, 120.0, 80.9, 80.1, 79.1, 87.5, 58.2, 46.9, 45.4, 42.1, 40.0, 34.9, 30.0, 29.3, 28.2 28.1, 27.8, 22.8.

MS (MALDI) calculated [M+H]: 724.45, found: 724.19.

¹³C NMR (75 MHz, CDCl₃) δ: 171.4, 165.8, 155.9, 154.5, 148.5, 121.3, 80.7, 79.6, 56.2, 51.8, 46.0, 42.9, 39.3, 38.7, 28.6, 25.5, 25.5, 15.6, 11.6. MS (MALDI) calculated [M+H]: 538.33, found: 538.06.

¹³C NMR (75 MHz, CDCl₃) δ: 169.9, 166.2, 156.2, 155.6, 154.4, 149.3, 144.5, 128.7, 127.0, 120.8, 80.5, 79.7, 79.1, 70.6, 68.0, 59.4, 45.7, 45.2, 42.4, 40.4, 39.8, 32.6, 29.4, 28.5, 25.7, 22.8. MS (MALDI) calculated [M+Na]: 917.49, found: 917.27.

¹³C NMR (75 MHz, CDCl₃) δ: 171.5, 165.8, 156.0, 154.5, 148.7, 121.3, 80.6, 79.5, 56.2, 52.9, 45.9, 42.8, 38.7, 33.0, 28.5, 19.3, 18.7. MS (MALDI) calculated [M+H]: 524.31, 524.06.

¹³C NMR (75 MHz, CDCl₃) δ: 171.2, 170.2, 168.0, 165.9, 155.7, 154.5, 144.7, 132.6, 131.2, 129.0, 128.9, 127.1, 121.8, 80.5, 79.8, 70.7, 68.4, 56.0, 42.7, 38.9, 38.4, 30.6, 29.1, 28.6.

MS (MALDI) calculated [M+Na]: 803.39, found: 803.19.

¹³C NMR (75 MHz, CDCl₃) δ: 168.6, 165.4, 155.3, 154.4, 149.2, 120.1, 82.2, 80.5, 79.7, 55.5, 46.4, 45.9, 42.7, 38.7, 34.7, 30.5, 28.5, 28.4, 15.5. MS (MALDI) calculated [M+H]: 613.33, 613.40.

¹³C NMR (75 MHz, CDCl₃) δ: 166.8, 156.4, 155.7, 154.5, 121.5, 80.9, 799, 79.3, 67.6, 63.1, 47.5, 45.9, 42.6, 40.5, 35.3, 29.8, 28.7, 28.6, 23.1, 18.9. MS (MALDI) calculated [M+H]: 640.40, found, 640.52.

¹³C NMR (75 MHz, CDCl₃) δ: 168.9, 165.6, 154.6, 120.8, 82.5, 80.8, 55.7, 46.1, 44.0, 42.6, 38.9, 36.5, 28.7, 28.3. MS (MALDI) calculated [M+H]: 539.31, found 539.41.

¹³C NMR (75 MHz, CDCl₃) δ: 165.8, 156.0, 154.6, 148.2, 121.6, 80.8, 79.7, 63.0, 60.7, 52.8, 45.9, 42.5, 33.1, 28.5, 19.2, 18.5. MS (MALDI) calculated [M+H]: 497.30, found: 497.44.

¹³C NMR (75 MHz, CDCl₃) δ: 170.0, 168.8, 165.2, 155.6, 154.4, 149.9, 144.5, 128.8, 128.2, 127.1, 121.0, 120.7, 82.1, 800.4, 79.8, 70.7, 55.4, 45.8, 45.2, 42.7, 40.2, 38.7, 28.5, 28.2.

MS (MALDI) calculated [M+H]: 838.44, found: 838.58.

¹³C NMR (75 MHz, CDCl₃) δ: 168.6, 165.3, 155.5, 154.3, 148.4, 120.1, 82.0, 80.4, 79.4, 55.6, 51.6, 45.8, 42.7, 39.2, 38.7, 28.4, 28.0, 25.3, 15.4, 11.6. MS (MALDI) calculated [M+H]: 595.37, found: 595.51.

¹³C NMR (75 MHz, CDCl₃) δ: 168.5, 165.1, 155.2, 154.1, 120.4, 81.8, 80.1, 79.4, 73.1, 63.4, 55.5, 48.0, 45.6, 44.5, 42.5, 38.5, 28.8, 28.2, 27.9, 27.4. MS (MALDI) calculated [M+H]: 625.38, found: 625.45.

The following method may be used to prepare protected monovalent compound z′″ (Scheme 15).

Characterization data for protected monovalent compound z′″ follows:

¹H NMR (CDCl₃, 300 MHz): δ 8.24-8.14 (m, 2H), 7.97-7.87 (s, 4H), 5.89-5.81 (m, 1H), 5.36-5.30 (m, 1H), 3.80-3.14 (m, 8H), 2.15-1.90 (m, 6H), 1.50-1.42 (s, 9H), 1.29-1.22 (m, 3H), 1.14-1.07 (m, 3H), 1.03-0.98 (m, 3H), 0.96-0.90 (m, 3H). Mass Spec (ESI) Calculated for [M+1]: 609.34, found: 609.35.

The following general method may be used to prepare protected monovalent compounds a″″ through b″″ (Scheme 16).

Characterization data for protected monovalent compounds a″″ through b″″ follows:

Calculated Mass: 568.25 found (ESI): 567.2421 (M−H)⁻.

Calculated mass: 625.27; found (ESI): 624.2646 (M−H)⁻.

The following method may be used to prepare protected monovalent compounds c″″ through e″″ (Scheme 17).

Characterization data for protected monovalent compounds c″″ through e″″ follows:

Desired MS 604.30 (M+H). MS Found (MALDI, m/z) 604.34 (M+H).

Desired MS 699.35 (M+H). MS Found (MALDI, m/z) 699.20 (M+H).

Desired MS 787.46 (M+H). MS Found (ESI, m/z) 787.46 (M+H).

Example 2 Synthesis of Bivalent Compounds Having a Triazine Core

The protected monovalent compounds may be reacted with a 1,3,5-triazine moiety having a labeling tag attached. An exemplary but non-limiting general procedure for synthesizing the 1,3,5-triazine bivalent compounds follows: The protected monovalent compound was deprotected with TFA in CH₂Cl₂. The deprotected monovalent compound was dissolved in THF and reacted at room temperature with a dichlorotriazine derivative in the presence of K₂CO₃. In the example that follows, the dichlorotriazine derivative is labeled with a fluorescein tag (i.e., DTAF). The solvent was removed at reduced pressure, and the product was sufficiently pure to use without further purification. The crude product was redissolved in DMSO, and a second equivalent of a deprotected monovalent compound was reacted at room temperature in the presence of K₂CO₃. Following workup and purification, bivalent peptide mimics having a 1,3,5-triazine core and a labeling tag were obtained. Morpholine may also be used in the first or second coupling steps. A representative synthesis of the 1,3,5-triazine bivalent compounds is presented in Scheme 18.

Example 3 Listing of Bivalent Triazine Compounds Prepared

Tables 1-7 provide listings of bivalent compounds prepared and experimental characterization of those compounds when available.

TABLE 1 Bivalent Compounds from Monovalent Compounds a-o Monovalent HPLC Purity (%) Compound Tag UV 254 nm Sedex ap 1 100 100 aa 1 100 100 bp 1 93 100 ba 1 86 100 bb 1 91 100 cp 1 100 100 ca 1 86 92 cb 1 85 92 cc 1 100 100 dp 1 85 92 da 1 86 100 db 1 92 100 dc 1 90 100 dd 1 92 100 ep 1 86 90 ea 1 92 94 eb 1 100 100 ec 1 94 100 ed 1 100 100 ee 1 100 100 fp 1 100 100 fa 1 100 100 fb 1 90 100 fc 1 100 100 fd 1 91 100 fe 1 89 100 ff 1 100 94 gp 1 88 98 ga 1 86 92 gb 1 100 100 gc 1 96 98 gd 1 87 00 ge 1 94 100 gf 1 96 100 gg 1 86 100 hp 1 98 100 ha 1 89 93 hb 1 93 100 hc 1 93 100 hd 1 93 100 he 1 93 100 hf 1 87 94 hg 1 96 98 hh 1 91 100 ip 1 92 87 ia 1 93 91 ib 1 100 100 ic 1 91 100 id 1 90 100 ie 1 100 100 if 1 100 100 ig 1 98 97 ih 1 92 100 ii 1 89 96 jp 1 100 100 ja 1 100 100 jb 1 100 100 jc 1 100 100 jd 1 100 100 je 1 100 100 jf 1 100 100 jg 1 96 100 jh 1 96 100 ji 1 100 100 jj 1 100 100 kp 1 94 99 ka 1 90 95 kb 1 100 100 kc 1 94 100 kd 1 100 100 ke 1 100 100 kf 1 86 93 kg 1 93 90 kh 1 100 100 ki 1 100 100 kj 1 100 100 kk 1 86 100 lp 1 87 100 la 1 88 94 lb 1 100 100 lc 1 97 100 ld 1 100 100 le 1 100 100 lf 1 87 100 lg 1 100 100 lh 1 100 100 li 1 100 100 lj 1 100 100 lk 1 100 100 ll 1 95 100 mp 1 92 97 ma 1 92 100 mb 1 86 92 mc 1 97 100 md 1 100 100 me 1 89 100 mf 1 100 100 mg 1 88 96 mh 1 88 87 mi 1 100 100 mj 1 100 100 mk 1 100 100 ml 1 100 100 mm 1 100 100 np 1 100 100 na 1 100 96 nb 1 100 100 nc 1 100 100 nd 1 100 100 ne 1 100 100 nf 1 100 98 ng 1 86 100 nh 1 92 100 ni 1 100 100 nj 1 100 100 nk 1 100 100 nl 1 100 100 nm 1 100 100 nn 1 100 100 op 1 100 100 oa 1 100 93 ob 1 87 93 oc 1 100 100 od 1 87 86 oe 1 90 92 of 1 100 100 og 1 90 94 oh 1 89 93 oi 1 89 95 oj 1 100 98 ok 1 88 93 ol 1 90 90 om 1 100 100 on 1 100 100 oo 1 100 91 ap 2 100 98 aa 2 93 100 bp 2 100 100 ba 2 90 100 bb 2 97 100 cp 2 100 100 ca 2 91 91 cb 2 86 91 cc 2 100 87 dp 2 100 100 da 2 100 100 db 2 87 100 dc 2 97 100 dd 2 100 100 ep 2 100 100 ea 2 100 100 eb 2 89 100 ec 2 86 92 ed 2 87 100 ee 2 100 100 fp 2 100 100 fa 2 90 85 fb 2 98 100 fc 2 87 91 fd 2 89 94 fe 2 89 93 ff 2 100 99 gp 2 100 100 ga 2 87 90 gb 2 91 92 gc 2 89 94 gd 2 89 100 ge 2 85 89 gf 2 100 100 gg 2 89 97 hp 2 89 87 ha 2 89 91 hb 2 90 87 hc 2 88 91 hd 2 92 89 he 2 89 90 hf 2 100 100 hg 2 100 100 hh 2 87 89 ip 2 100 100 ia 2 95 100 ib 2 98 100 ic 2 97 96 id 2 91 90 ie 2 92 100 if 2 96 92 ig 2 100 92 ih 2 93 91 ii 2 91 95 jp 2 100 97 ja 2 100 88 jb 2 95 100 jc 2 93 100 jd 2 87 91 je 2 87 88 jf 2 100 94 jg 2 100 100 jh 2 95 100 ji 2 90 91 jj 2 96 100 kp 2 100 100 ka 2 95 100 kb 2 100 100 kc 2 96 95 kd 2 92 90 ke 2 97 94 kf 2 90 92 kg 2 100 92 kh 2 94 93 ki 2 87 90 kj 2 91 92 kk 2 98 97 lp 2 96 100 la 2 99 100 lb 2 90 88 lc 2 88 86 ld 2 86 85 le 2 86 89 lf 2 86 98 lg 2 86 86 lh 2 87 87 li 2 89 86 lj 2 88 85 lk 2 87 88 ll 2 91 96 mp 2 100 100 ma 2 86 86 mb 2 100 100 mc 2 86 100 md 2 87 94 me 2 96 100 mf 2 86 85 mg 2 90 90 mh 2 89 88 mi 2 100 100 mj 2 89 95 mk 2 94 100 ml 2 92 92 mm 2 91 89 np 2 100 100 na 2 89 100 nb 2 85 100 nc 2 93 90 nd 2 92 100 ne 2 90 95 nf 2 100 92 ng 2 85 90 nh 2 97 88 ni 2 87 94 nj 2 87 92 nk 2 85 87 nl 2 87 86 nm 2 86 100 nn 2 96 96 op 2 100 98 oa 2 92 87 ob 2 86 100 oc 2 90 85 od 2 100 100 oe 2 85 100 of 2 87 100 og 2 85 92 oh 2 88 93 oi 2 95 100 oj 2 100 100 ok 2 94 100 ol 2 94 100 om 2 87 97 on 2 91 85 oo 2 90 92 ap 3 76 100 aa 3 95 100 bp 3 70 92 ba 3 88 96 bb 3 80 93 cp 3 75 94 ca 3 80 96 cb 3 83 95 cc 3 93 93 db 3 94 100 da 3 80 95 db 3 81 96 dc 3 95 92 dd 3 92 100 ep 3 96 100 ea 3 89 97 eb 3 88 94 ec 3 99 100 ed 3 95 98 ee 3 96 100 fp 3 96 99 fa 3 89 93 fb 3 85 95 fc 3 76 91 fd 3 92 92 fe 3 93 97 ff 3 95 94 gp 3 76 94 ga 3 83 91 gb 3 85 98 gc 3 80 93 gd 3 85 90 ge 3 94 97 gf 3 75 94 gg 3 85 96 hp 3 95 100 ha 3 85 100 hb 3 84 91 hc 3 81 98 hd 3 85 100 he 3 86 94 hf 3 85 96 hg 3 80 100 hh 3 80 90 ip 3 93 100 ia 3 85 94 ib 3 95 100 ic 3 93 100 id 3 92 95 ie 3 92 87 if 3 87 100 ig 3 93 95 ih 3 95 100 ii 3 90 88 jp 3 96 100 ja 3 91 94 jb 3 91 95 jc 3 91 94 jd 3 92 100 je 3 91 86 jf 3 92 94 jg 3 89 97 jh 3 88 91 ji 3 95 100 jj 3 95 100 kp 3 95 100 ka 3 88 94 kb 3 88 91 kc 3 94 100 kd 3 93 100 ke 3 92 90 kf 3 91 100 kg 3 92 95 kh 3 90 89 ki 3 90 87 kj 3 95 100 kk 3 90 87 lp 3 85 100 la 3 85 100 lb 3 87 92 lc 3 87 95 ld 3 85 97 le 3 93 94 lf 3 78 92 lg 3 87 97 lh 3 86 90 li 3 92 90 lj 3 87 90 lk 3 93 94 ll 3 85 93 mp 3 98 100 ma 3 93 96 mb 3 81 100 mc 3 74 100 md 3 94 97 me 3 93 94 mf 3 96 98 mg 3 93 100 mh 3 82 97 mi 3 90 91 mj 3 95 100 mk 3 91 97 ml 3 89 94 mm 3 98 99 np 3 91 100 na 3 78 95 nb 3 82 95 nc 3 77 90 nd 3 90 93 ne 3 94 96 nf 3 96 100 ng 3 78 94 nh 3 78 94 ni 3 95 100 nj 3 91 94 nk 3 89 91 nl 3 81 94 nm 3 94 95 nn 3 95 100 op 3 78 95 oa 3 89 96 ob 3 85 92 oc 3 90 94 od 3 86 97 oe 3 85 91 of 3 85 100 og 3 85 94 oh 3 92 97 oi 3 95 100 oj 3 91 91 ok 3 93 98 ol 3 85 94 om 3 85 100 on 3 95 100 oo 3 86 92 ap 4 aa 4 bp 4 ba 4 bb 4 cp 4 ca 4 cb 4 cc 4 dp 4 da 4 db 4 dc 4 dd 4 ep 4 ea 4 eb 4 ec 4 ed 4 ee 4 fp 4 fa 4 fb 4 fc 4 fd 4 fe 4 ff 4 gp 4 ga 4 gb 4 gc 4 gd 4 ge 4 gf 4 gg 4 hp 4 ha 4 hb 4 hc 4 hd 4 he 4 hf 4 hg 4 hh 4 ip 4 ia 4 ib 4 ic 4 id 4 ie 4 if 4 ig 4 ih 4 ii 4 jp 4 ja 4 jb 4 jc 4 jd 4 je 4 jf 4 jg 4 jh 4 ji 4 jj 4 kp 4 ka 4 kb 4 kc 4 kd 4 ke 4 kf 4 kg 4 kh 4 ki 4 kj 4 kk 4 lp 4 la 4 lb 4 lc 4 ld 4 le 4 lf 4 lg 4 lh 4 li 4 lj 4 lk 4 ll 4 mp 4 ma 4 mb 4 mc 4 md 4 me 4 mf 4 mg 4 mh 4 mi 4 mj 4 mk 4 ml 4 mm 4 np 4 na 4 nb 4 nc 4 nd 4 ne 4 nf 4 ng 4 nh 4 ni 4 nj 4 nk 4 nl 4 nm 4 nn 4 op 4 oa 4 ob 4 oc 4 od 4 oe 4 of 4 og 4 oh 4 oi 4 oj 4 ok 4 ol 4 om 4 on 4 oo 4

TABLE 2 Representative Mass Spec Results for Bivalent Compounds of Monovalent Compounds a-o Monovalent Mass (M + H)⁺ Compound Tag theoretical found ba 1 1012 1012 cp 1 1070 1070 dd 1 902 902 ed 1 916 916 gf 1 1015 1015 gg 1 1044 1044 ia 1 1054 1054 ib 1 998 998 ig 1 1041 1041 jp 1 860 860 jf 1 1055 1055 jh 1 1098 1098 jj 1 1124 1124 kg 1 1027 1027 kj 1 1068 1068 le 1 1015 1015 mp 1 986 986 ml 1 1043 1043 np 1 1114 1114 ne 1 1021 1021 nf 1 1050 1050 ng 1 1078 1078 nh 1 1093 1093 nj 1 1119 1119 nk 1 1063 1063 nm 1 1050 1050 og 1 1055 1055 oj 1 1096 1096 aa 2 936 936 cc 2 938 938 da 2 853 853 ea 2 867 867 ff 2 854 854 ic 2 923 923 ii 2 908 908 jb 2 908 908 jc 2 965 965 jf 2 923 923 kp 2 672 672 kb 2 852 852 kc 2 909 909 mk 2 867 867 ml 2 911 911 mm 2 854 854 np 2 723 723 nc 2 960 960 nd 2 876 876 nn 2 982 982 oj 2 964 964 ok 2 908 908 oo 2 936 936 cc 3 909 909 dp 3 589 598 dd 3 741 741 ee 3 769 769 hc 3 911 911 ip 3 658 658 if 3 852 852 oi 3 894 894 la 3 924 924 ll 3 940 940 mg 3 854 854 ml 3 882 882 kp 3 644 644 ok 3 880 880 kk 3 852 852 ne 3 861 861 on 3 931 931 ja 3 936 936 ji 3 922 922 jj 3 964 964

TABLE 3 Bivalent Compounds from Monovalent Compounds f′ to m′ HPLC purity Monovalent mass mass (%) Compound Tag (desired) (found) UV (254 nm) pp 2 465.23 465.03 100 g′p 2 703.37 703.28 100 g′g′ 2 941.52 941.48 100 h′p 2 759.44 759.36 100 h′g′ 2 997.58 997.55 100 h′h′ 2 1053.64 1053.65 100 k′p 2 958.56 958.67 100 k′g′ 2 1196.70 1196.79 100 k′h′ 2 1252.76 1252.82 100 k′k′ 2 1451.88 1452.05 100 i′p 2 775.40 775.31 100 i′g′ 2 1013.54 1013.52 100 i′h′ 2 1069.60 1069.49 100 i′k′ 2 1268.72 1268.83 97 i′i′ 2 1085.56 1085.51 100 l′p 2 886.54 886.55 100 l′g′ 2 1124.68 1124.70 100 l′h′ 2 1180.74 1180.96 100 l′k′ 2 1379.86 1379.95 100 l′i′ 2 1196.70 1196.78 100 l′l′ 2 1307.84 1308.06 100 m′p 2 942.60 942.74 100 m′g′ 2 1180.74 1180.83 100 m′h′ 2 1236.81 1236.86 100 m′k′ 2 1435.93 1436.04 100 m′i′ 2 1252.76 1252.87 100 m′l′ 2 1363.90 1364.08 100 m′m′ 2 1419.97 1420.04 100 j′p 2 859.49 859.37 100 j′g′ 2 1097.63 1097.69 100 j′h′ 2 1153.70 1153.79 100 j′k′ 2 1352.82 1352.93 100 j′i′ 2 1169.65 1169.72 100 j′l′ 2 1280.80 1280.79 100 j′m′ 2 1336.86 1336.87 100 j′j′ 2 1253.75 1253.73 100 f′p 2 676.33 676.31 100 f′g′ 2 914.47 914.32 98 f′h′ 2 970.53 970.54 100 f′k′ 2 1169.65 1169.82 100 f′i′ 2 986.49 986.41 100 f′l′ 2 1097.63 1097.72 100 f′m′ 2 1153.70 1153.71 100 f′j′ 2 1070.59 1070.69 100 f′f′ 2 887.42 887.36 100

TABLE 4 Bivalent Compounds from Monovalent Compounds h″ to w″ Monovalent HPLC Purity (%) Compounds Tag UV 254 nm Sedex h″p 1 98 99 h″h″ 1 97 97 i″p 1 99 99 i″h″ 1 90 95 i″i″ 1 100 97 j″p 1 95 100 j″h″ 1 94 100 j″i″ 1 92 100 j″j″ 1 87 97 k″p 1 97 100 k″h″ 1 91 97 k″i″ 1 90 96 k″j″ 1 86 98 k″k″ 1 95 100 l″p 1 95 100 l″h″ 1 90 98 l″i″ 1 94 99 l″j″ 1 87 100 l″k″ 1 94 100 l″l″ 1 100 100 m″p 1 99 100 m″h″ 1 99 99 m″i″ 1 91 96 m″j″ 1 85 97 m″k″ 1 91 97 m″l″ 1 90 96 m″m″ 1 100 98 n″p 1 95 99 n″h″ 1 92 100 n″i″ 1 92 99 n″j″ 1 86 91 n″k″ 1 88 100 n″l″ 1 88 100 n″m″ 1 92 97 n″n″ 1 87 100 o″p 1 97 100 o″h″ 1 90 97 o″i″ 1 94 96 o″j″ 1 90 96 o″k″ 1 94 100 o″l″ 1 92 98 o″m″ 1 93 96 o″n″ 1 93 97 o″o″ 1 92 100 p″p 1 92 98 p″h″ 1 90 96 p″i″ 1 92 96 p″j″ 1 87 97 p″k″ 1 87 100 p″l″ 1 100 100 p″m″ 1 94 98 p″n″ 1 90 98 p″o″ 1 86 98 p″p″ 1 100 100 q″p 1 100 100 q″h″ 1 96 96 q″i″ 1 91 94 q″j″ 1 90 97 q″k″ 1 86 97 q″l″ 1 88 97 q″m″ 1 99 99 q″n″ 1 90 95 q″o″ 1 85 97 q″p″ 1 90 97 q″q″ 1 100 98 r″p 1 100 100 r″h″ 1 86 98 r″i″ 1 100 100 r″j″ 1 96 96 r″k″ 1 95 95 r″l″ 1 90 99 r″m″ 1 90 100 r″n″ 1 100 100 r″o″ 1 98 100 r″p″ 1 85 100 r″q″ 1 87 100 r″r″ 1 86 100 s″p 1 98 100 s″h″ 1 97 98 s″i″ 1 85 95 s″j″ 1 85 97 s″k″ 1 85 93 s″l″ 1 86 97 s″m″ 1 92 98 s″n″ 1 92 10 s″o″ 1 95 100 s″p″ 1 99 97 s″q″ 1 92 99 s″r″ 1 88 99 s″s″ 1 98 100 t″p 1 88 94 t″h″ 1 85 95 t″i″ 1 90 97 t″j″ 1 98 100 t″k″ 1 90 98 t″l″ 1 87 95 t″m″ 1 95 96 t″n″ 1 93 100 t″o″ 1 98 100 t″p″ 1 97 100 t″q″ 1 99 95 t″r″ 1 85 89 t″s″ 1 86 91 t″t″ 1 85 86 u″p 1 100 100 u″h″ 1 87 90 u″i″ 1 85 96 u″j″ 1 85 97 u″k″ 1 85 95 u″l″ 1 93 97 u″m″ 1 91 97 u″n″ 1 97 95 u″o″ 1 98 100 u″p″ 1 85 88 u″q″ 1 100 100 u″r″ 1 99 96 u″s″ 1 95 100 u″t″ 1 91 99 u″u″ 1 99 100 v″p 1 93 98 v″h″ 1 86 95 v″i″ 1 88 95 v″j″ 1 88 96 v″k″ 1 100 100 v″l″ 1 99 99 v″m″ 1 87 96 v″n″ 1 87 96 v″o″ 1 99 99 v″p″ 1 97 97 v″q″ 1 90 90 v″r″ 1 85 93 v″s″ 1 85 85 v″t″ 1 85 94 v″u″ 1 85 94 v″v″ 1 96 96 w″p 1 91 95 w″h″ 1 90 98 w″i″ 1 95 95 w″j″ 1 90 90 w″k″ 1 90 90 w″l″ 1 85 85 w″m″ 1 85 85 w″n″ 1 88 88 w″o″ 1 85 85 w″p″ 1 90 90 w″q″ 1 97 97 w″r″ 1 90 90 w″s″ 1 88 88 w″t″ 1 87 87 w″u″ 1 85 85 w″v″ 1 90 90 w″w″ 1 90 90 h″p 3 99 100 h″h″ 3 94 90 i″p 3 100 100 i″h″ 3 92 90 i″i″ 3 100 98 j″p 3 100 100 j″h″ 3 96 100 j″i″ 3 93 98 j″j″ 3 95 90 k″p 3 99 97 k″h″ 3 100 100 k″i″ 3 100 100 k″j″ 3 94 100 k″k″ 3 95 95 l″p 3 100 100 l″h″ 3 96 100 l″i″ 3 99 100 l″j″ 3 100 100 l″k″ 3 100 100 l″l″ 3 91 100 m″p 3 98 100 m″h″ 3 97 92 m″i″ 3 91 90 m″j″ 3 100 100 m″k″ 3 100 100 m″l″ 3 100 97 m″m″ 3 100 100 n″p 3 100 100 n″h″ 3 98 100 n″i″ 3 88 97 n″j″ 3 100 100 n″k″ 3 97 97 n″l″ 3 100 100 n″m″ 3 94 100 n″n″ 3 100 100 o″p 3 91 95 o″h″ 3 90 100 o″i″ 3 97 100 o″j″ 3 100 100 o″k″ 3 100 100 o″l″ 3 96 100 o″m″ 3 97 91 o″n″ 3 92 100 o″o″ 3 93 93 p″p 3 100 100 p″h″ 3 97 97 p″i″ 3 98 100 p″j″ 3 100 100 p″k″ 3 100 100 p″l″ 3 97 100 p″m″ 3 98 100 p″n″ 3 100 100 p″o″ 3 100 100 p″p″ 3 94 90 q″p 3 100 100 q″h″ 3 94 100 q″i″ 3 97 99 q″j″ 3 100 100 q″k″ 3 100 100 q″l″ 3 95 100 q″m″ 3 96 100 q″n″ 3 100 100 q″o″ 3 98 100 q″p″ 3 100 100 q″q″ 3 97 92 s″p 3 93 100 s″h″ 3 92 91 s″i″ 3 100 100 s″j″ 3 100 100 s″k″ 3 100 100 s″l″ 3 100 100 s″m″ 3 81 100 s″n″ 3 91 98 s″o″ 3 100 100 s″p″ 3 100 100 s″q″ 3 92 93 s″s″ 3 86 96 t″p 3 98 99 t″h″ 3 93 98 t″i″ 3 100 100 t″j″ 3 95 100 t″k″ 3 100 100 t″l″ 3 100 100 t″m″ 3 100 100 t″n″ 3 92 100 t″o″ 3 100 100 t″p″ 3 100 100 t″q″ 3 100 100 t″s′′′ 3 86 91 t″t″ 3 97 100 u″p 3 98 95 u″h″ 3 100 100 u″i″ 3 100 100 u″j″ 3 84 100 u″k″ 3 100 100 u″l″ 3 100 100 u″m″ 3 95 98 u″n″ 3 89 91 u″o″ 3 100 100 u″p″ 3 100 100 u″q″ 3 92 97 u″s″ 3 100 100 u″t″ 3 100 100 u″u″ 3 100 100 v″p 3 100 100 v″h″ 3 82 100 v″i″ 3 100 100 v″j″ 3 100 100 v″k″ 3 96 96 v″l″ 3 100 97 v″m″ 3 100 100 v″n″ 3 100 100 v″o″ 3 99 100 v″p″ 3 100 100 v″q″ 3 96 100 v″s″ 3 100 99 v″t″ 3 94 100 v″u″ 3 100 100 v″v″ 3 100 100 w″p 3 98 100 w″h″ 3 82 90 w″i″ 3 96 100 w″j″ 3 100 100 w″k″ 3 90 95 w″l″ 3 97 100 w″m″ 3 100 100 w″n″ 3 92 92 w″o″ 3 100 100 w″p″ 3 91 91 w″q″ 3 100 100 w″s″ 3 89 90 w″t″ 3 93 100 w″u″ 3 97 100 w″v″ 3 100 100 w″w″ 3 100 100

TABLE 5 Representative Mass Spec Results for Bivalent Compounds of Monovalent Compounds h″ to w″ Monovalent Mass Compounds Tag theoretical found h″h″ 1 1233.53 (M + K) 1233.52 i″i″ 1 1096.62 (M + 2) 1096.62 k″p 1 861.42 (M + 1) 861.45 l″k″ 1 1127.58 (M + 2) 1127.56 m″h″ 1 1233.52 (M + K) 1233.56 n″n″ 1 1279 (M + K) 1279.60 o″i″ 1 1148 (M + K) 1148.62 o″o″ 1 1126.64 (M + 2) 1126.64 p″o″ 1 1164.53 (M + K) 1164.54 r″p 1 893.36 (M + 2) 893.37 r″j″ 1 1237.52 (N + Na) 1237.61 s″p″ 1 1100.51 (M + 1) 1100.57 s″s″ 1 1095.49 (M + Na) 1095.56 t″o″ 1 1100.52 (M + 1) 1100.61 t″t″ 1 1075.41 (M + 1) 1075.47 u″n″ 1 1164.52 (M + Na) 1164.56 u″u″ 1 1043.49 (M + 1) 1043.62 v″l″ 1 1178.50 (M + 2) 1178.59 w″i″ 1 1256.54 (M + K) 1256.54 w″r″ 1 1287.50 (M + Na) 1287.55 h″h″ 3 1035.60 (M + H) 1035.63 i″i″ 3 935.64 (M + H) 935.64 l″j″ 3 1024.60 (M + H) 1024.64 m″m″ 3 1035.60 (M + H) 1035.64 n″k″ 3 1023.65 (M + H) 1023.68 o″o″ 3 965.67 (M + H) 965.71 p″i″ 3 951.60 (M + H) 951.64 p″n″ 3 1024.60 (M + H) 1024.64 q″h″ 3 1035.60 (M + H) 1035.57 q″l″ 3 1001.58 (M + H) 1001.62 q″q″ 3 1035.60 (M + H) 1035.60 s″j″ 3 997.60 (M + H) 997.57 s″o″ 3 939.61 (M + H) 939.65 s″s″ 3 913.56 (M + H) 913.58 t″p 3 1035.60 (M + H) 1035.57 t″l″ 3 941.51 (M + H) 941.55 u″n″ 3 982.59 (M + H) 982.61 u″u″ 3 883.54 (M + H) 883.56 v″i″ 3 1001.58 (M + H) 1001.61 v″p″ 3 1017.54 (M + H) 1017.56 w″m″ 3 1108.60 (M + H) 1108.63

TABLE 6 Bivalent Compounds from Monovalent Compounds x″ to k′″ Monovalent Mass Spec (M + H)⁺ HPLC Purity (%) Compounds Tag calculated found UV 254 nm SEDEX x″x″ 3 1135.74 1135.50 88 100 x″y″ 3 1195.74 1195.54 97 100 x″z″ 3 1234.81 1234.59 98 100 x″a″ 3 1162.79 1162.51 93 100 x″b′″ 3 1192.8 1192.78 98 100 x″c′″ 3 1218.85 1218.61 100 100 x″d′″ 3 1246.86 1246.74 100 100 y″y″ 3 1255.75 1255.72 100 100 y″z″ 3 1294.81 1294.78 91 95 y″a′″ 3 1222.79 1222.62 100 100 y″b′″ 3 1252.80 1252.66 95 100 y″c′″ 3 1278.85 1278.70 93 100 y″d′″ 3 1306.86 1306.68 99 100 z″z″ 3 1333.88 1333.81 90 99 z″a′″ 3 1261.85 1261.88 89 90 z″b′″ 3 1291.87 1291.96 99 100 z″c′″ 3 1317.92 1317.97 94 100 z″d′″ 3 1345.92 1345.91 99 98 a′″a′″ 3 1189.83 1189.64 100 100 a′″b′″ 3 1219.84 1219.71 98 95 a′″c′″ 3 1245.92 1245.73 98 99 a′″d′″ 3 1273.90 1273.83 87 96 b′″b′″ 3 1249.85 1249.71 98 99 b′″c′″ 3 1275.91 1275.68 94 99 b′″d′″ 3 1303.91 1303.74 98 100 c′″c′″ 3 1301.96 1301.80 98 100 c′″d′″ 3 1329.96 1329.85 100 100 d′″d′″ 3 1357.97 1357.69 100 100 x″p 3 786.49 786.26 91 100 y″p 3 846.49 846.26 100 100 z″p 3 885.56 885.47 98 100 a′″p 3 813.54 813.34 95 100 b′″p 3 843.55 843.31 91 99 c′″p 3 869.6 869.40 82 94 d′″p 3 897.61 897.41 95 100 k′″p 3 885.11 885.52 100 100 j′″p 3 897.16 897.58 100 100 h′″p 3 843.07 843.54 100 100 g′″p 3 813.04 813.37 100 100 f′″p 3 785.98 786.49 100 100 i′″p 3 869.15 869.40 100 100 e′″p 3 846.09 846.33 100 100 i′″i′″ 3 1301.8 1302.04 100 100 i′″g′″ 3 1245.69 1245.87 100 100 i′″k′″ 3 1317.75 1317.93 100 100 i′″h′″ 3 1275.72 1275.82 100 100 i′″f′″ 3 1218.62 1218.89 100 100 i′″j′″ 3 1329.81 1329.98 100 100 i′″e′″ 3 1278.74 1278.85 100 100 g′″g′″ 3 1189.58 1189.73 100 100 g′″k′″ 3 1261.65 1261.98 100 100 g′″h′″ 3 1219.61 1219.75 100 100 g′″f′″ 3 1162.52 1162.69 100 100 g′″j′″ 3 1273.70 1273.76 100 100 g′″e′″ 3 1222.63 1222.82 100 100 k′″k′″ 3 1333.71 1333.86 100 100 k′″h′″ 3 1291.67 1291.86 100 100 k′″f′″ 3 1234.58 1234.73 100 100 k′″j′″ 3 1345.77 1345.84 100 100 k′″e′″ 3 1294.70 1294.78 100 100 h′″h′″ 3 1249.64 1249.78 100 100 h′″f′″ 3 1192.54 1192.80 100 100 h′″j′″ 3 1303.73 1303.86 100 100 h′″e′″ 3 1252.66 1252.79 100 100 f′″f′″ 3 1135.45 1135.60 100 100 f′″j′″ 3 1246.64 1246.85 100 100 f′″e′″ 3 1195.57 1195.64 100 100 j′″j′″ 3 1357.82 1357.93 98 100 j′″e′″ 3 1306.75 1306.68 100 100 e′″e′″ 3 1255.68 1255.68 100 100 h′″y″ 3 1252.66 1252.53 100 100 k′″y″ 3 1294.70 1294.58 100 100 g′″y″ 3 1222.63 1222.59 100 100 j′″y″ 3 1306.75 1306.63 100 100 e′″y″ 3 1255.68 1255.62 100 100 i′″c′″ 3 1301.8 1301.76 100 100 e′″c′″ 3 1278.74 1278.73 100 100 f′″c′″ 3 1218.62 1218.68 100 100 h′″c′″ 3 1275.72 1275.78 100 100 e′″x″ 3 1195.57 1195.61 97 100 e′″b′″ 3 1252.66 1252.61 100 100 i′″b′″ 3 1275.72 1275.64 100 100 j′″x″ 3 1246.64 1246.61 95 99 g′″c′″ 3 1245.69 1246.04 100 100 k′″c′″ 3 1317.75 1318.13 99 100 i′″z″ 3 1317.75 1318.07 100 100 k′″z″ 3 1333.71 1333.88 100 100 h′″z″ 3 1291.67 1291.94 100 100 f′″z″ 3 1234.58 1234.77 99 100 j′″z″ 3 1345.77 1346.13 100 100 e′″z″ 3 1294.70 1294.92 100 100 f′″a′″ 3 1162.52 1162.87 98 100 f′″b′″ 3 1192.54 1192.93 100 100 i′″x″ 3 1218.62 1218.96 100 100 g′″x″ 3 1162.52 1162.88 100 100 k′″x″ 3 1234.58 1234.94 100 100 f′″x″ 3 1135.45 1135.90 100 100 gi′″d′″ 3 1273.70 1274.06 100 100 f′″d′″ 3 1246.64 1247.00 100 100 i′″y″ 3 1278.74 100 100 i′″d′″ 3 1329.81 i′″a′″ 3 1245.69 98 100 g′″z″ 3 1261.65 g′″a′″ 3 1189.58 k′″d′″ 3 1345.77 k′″a′″ 3 1261.65 99 100 g′″b′″ 3 1219.61 95 100 k′″b′″ 3 1291.67 97 100 h′″a′″ 3 1219.61 100 100 h′″b′″ 3 1249.64 98 100 h′″x″ 3 1192.54 h′″d′″ 3 1303.73 99 100 f′″y″ 3 1195.57 j′″c′″ 3 1329.81 j′″a′″ 3 1273.7 j′″b′″ 3 1303.73 94 99 j′″d′″ 3 1357.82 100 100 e′″a′″ 3 1222.63 e′″d′″ 3 1306.75

TABLE 7 Bivalent Compounds from Monovalent Compounds c′′′′ to e′′′′ HPLC purity Monovalent Mass Mass UV 254 nm Compounds Tag (desired) (found) (%) c′′′′c′′′′ 1 1629.67 1629.65 100 c′′′′d′′′′ 1 1724.72 1724.49 100 d′′′′d′′′′ 1 1819.77 1819.62 100 c′′′′e′′′′ 1 1812.83 1812.94 98 d′′′′e′′′′ 1 1907.88 1907.91 100 e′′′′e′′′′ 1 1995.99 1996.06 100 c′′′′c′′′′ 3 1469.71 1469.68 100 d′′′′d′′′′ 3 1659.81 1659.91 100 e′′′′e′′′′ 3 1836.03 1836.27 100

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the disclosure to various usages and conditions. The embodiments described hereinabove are meant to be illustrative only and should not be taken as limiting of the scope of the disclosure, which is defined in the following claims. 

1. A compound having the structure selected from the group consisting of:

wherein R₁ and R₂ are comprised by at least one moiety comprising an amino acid side chain, and wherein R₁ and R₂ comprise non-peptidic bonds; wherein X1 comprises a core molecule selected from the group consisting of heteroarylenes, arylenes and heterocyclenes and a nucleophilic moiety bound to said core molecule; and wherein K₁ and K₂ comprise at least one spacer atom between said core molecule and said at least one moiety comprising an amino acid side chain.
 2. The compound of claim 1, further comprising at least one 1,2,3-triazine moiety bound to said core molecule.
 3. The compound of claim 1, wherein R₁ and R₂ comprise at least one structural fragment selected from the group consisting of:

wherein R₁ and R₂ are independently selected.
 4. The compound of claim 1, wherein said nucleophilic moiety comprises a moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof.
 5. The compound of claim 1, wherein said nucleophilic moiety is bound directly to X1.
 6. The compound of claim 1, wherein said nucleophilic moiety is bound to X1 through at least one spacer atom.
 7. The compound of claim 1, wherein said core molecule comprises a moiety selected from the group consisting of a phenyl ring, a 1,2,3-triazole ring, a diketopiperazine ring, a 1,3,4-oxadiazole ring, a pyridine ring, and any substituted derivative or analog thereof.
 8. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof.
 9. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof; wherein Z2 comprises a moiety selected from the group consisting of —CH₂—, —CH₂CH₂— and —CH₂CH₂O—; and wherein n1 is an integer from 1-20.
 10. The compound of claim 9, wherein said compound has the structure:


11. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrollidine, azetidine, and any derivative or analog thereof; and wherein Z3 and Z4 comprise moieties independently selected from the group consisting of CO₂R₃, CONR₄R₅, and CH₂OH, wherein R₃ is selected from the group consisting of hydrogen and alkyl, and wherein R₄ and R₅ are independently selected from the group consisting of hydrogen and alkyl.
 12. The compound of claim 11, wherein said compound has the structure:

wherein R₆ and R₇ are independently selected from the group consisting of hydrogen and alkyl.
 13. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof.
 14. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrollidine, azetidine, and any derivative or analog thereof; wherein Z2 comprises a moiety selected from the group consisting of —CH₂—, —CH₂CH₂— and —CH₂CH₂O—; and wherein n1 is an integer from 1-20.
 15. The compound of claim 14, wherein said compound has the structure:


16. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof, and wherein R₈ and R₉ are each independently selected from the group consisting of hydrogen and alkyl.
 17. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof; and wherein R₁₀ and R₁₁ are independently selected from the group consisting of hydrogen and alkyl.
 18. The compound of claim 1, wherein said compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof.
 19. The compound of claim 1, wherein the compound has the structure:

wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof.
 20. The compound of claim 1, wherein said compound is selected from the group consisting of:


21. A compound having the structure:

wherein A1 comprises a macrocyclic ring comprising at least two amino acids, wherein said at least two amino acids are bound to each other in a ring comprising at least one peptide bond; wherein Z1 comprises a nucleophilic moiety selected from the group consisting of piperidine, piperazine, pyrrolidine, azetidine, and any derivative or analog thereof; and wherein S1 comprises a spacer group having at least one carbonyl moiety, wherein S1 does not comprise glycine.
 22. The compound of claim 21, wherein said compound is selected from the group consisting of:


23. A compound having the structure:

wherein B1 is a core molecule selected from the group consisting of heteroarylenes, arylenes, and heterocyclenes; and wherein P1 and P2 comprise an organic moiety comprising removal of a hydrogen atom from the compounds of claims 1 or 21, and wherein P1 and P2 are independently selected.
 24. The compound of claim 23 further comprising a labeling tag T1 bound to B1.
 25. The compound of claim 23 further comprising a third organic moiety comprising removal of a hydrogen atom from the compounds of claims 1 or 21 bound to B1, wherein said third organic moiety is selected independently of P1 and P2.
 26. A compound having the structure:

wherein P3 and P4 comprise an organic moiety comprising removal of a hydrogen atom from the nitrogen atom of the piperidine or piperazine ring of any of the compounds of claims 20 or 22, and wherein P3 and P4 are independently selected; and wherein P5 comprises a moiety selected from the group consisting of an organic moiety comprising removal of a hydrogen atom from the nitrogen atom of the piperidine or piperazine ring of any of the compounds of claims 20 or 22 and a labeling tag T1, wherein P5 is selected independently of P3 and P4.
 27. The compound of claim 26, wherein said compound has the structure:


28. The compound of claim 27, wherein at least one of P3 and P4 further comprise a morpholinyl group, with the proviso that both P3 and P4 are not a morpholinyl group.
 29. The compound of claims 24 or 26, wherein T1 is selected from the group consisting of a fluorescein tag, a biotin tag, a polyether tag, and a 1,2,3-triazole-functionalized polyether tag.
 30. The compound of claim 29, wherein T1 is selected from the group consisting of:


31. The compound of claim 28 comprising a combinatorial library, wherein compounds comprising the library are expressed in the shorthand form P3P4T1, and wherein: 1) P3 is selected from the group consisting of a, A, b, B, C, C, d, D, e, E, f, F, g, G, h, H, i, I, j, J, k, K, l, L, m, M, n, N, o, O, p, q, Q, r, R, s, S, t, T, u, U, v, V, w, W, x, X, y, Y, z, Z, a′, A′, b′, B′, c′, C′, d′, D′, e′, E′, f′, F′, g′, G′, h′, H′, i′, I′, j′, J′, k′, K′, l′, L′, m′, M′, n′, N′, o′, O′, p′, P′, q′, Q′, r′, R′, s′, S′, t′, T′, u′, U′, v′, V′, w′, W′, x′, X′, y′, Y′, z′, Z′, a″, A″, b″, B″c″, C″, d″, D″, e″, E″, f″, F″, g″, G″, h″, H″, i″, I″, j″, J″, k″, K″, l″, L″, m″, M″, n″, N″, o″, O″, p″, P″, q″, Q″, r″, R″, s″, S″, t″, T″, u″, U″, v″, V″, w″, W″, x″, X″, y″, Y″, z″, Z″, a′″, A′″, b′″, B′″, c′″, C′″, d′″, D′″, e′″, E′″, f′″, F′″, g′″, G′″, h′″, H′″, i′″, I′″, j′″, J′″, k′″, K′″, l′″, L′″, m′″, M′″, n′″, N′″, o′″, O′″, p′″, P′″, q′″, Q′″, r′″, R′″, s′″, S′″, t′″, T′″, u′″, U′″, V′″, v′″, w′″, W′″, x′″, X′″, y′″, Y′″, z′″, Z′″, a″″, A″″, b″″, B″″, c″″, C″″, d″″, D″″, e″″, and E″″; 2) P4 is selected from the group consisting of a, A, b, B, C, C, d, D, e, E, f, F, g, G, h, H, i, I, j, J, k, K, l, L, m, M, n, N, o, O, p, q, Q, r, R, s, S, t, T, u, U, v, V, w, W, x, X, y, Y, z, Z, a′, A′, b′, B′, c′, C′, d′, D′, e′, E′, f′, F′, g′, G′, h′, H′, i′, I′, j′, J′, k′, K′, l′, L′, m′, M′, n′, N′, o′, O′, p′, P′, q′, Q′, r′, R′, s′, S′, t′, T′, u′, U′, v′, V′, w′, W′, x′, X′, y′, Y′, z′, Z′, a″, A″, b″, B″c″, C″, d″, D″, e″, E″, f″, F″, g″, G″, h″, H″, i″, I″, j″, J″, k″, K″, l″, L″, m″, M″, n″, N″, o″, O″, p″, P″, q″, Q″, r″, R″, s″, S″, t″, T″, u″, U″, v″, V″, w″, W″, x″, X″, y″, Y″, z″, Z″, a′″, A′″, b′″, B′″, c′″, C′″, d′″, D′″, e′″, E′″, f′″, F′″, g′″, G′″, h′″, H′″, i′″, I′″, j′″, J′″, k′″, K′″, l′″, L′″, m′″, M′″, n′″, N′″, o′″, O′″, p′″, P′″, q′″, Q′″, r′″, R′″, s′″, S′″, t′″, T′″, u′″, U′″, V′″, v′″, w′″, W′″, x′″, X′″, y′″, Y′″, z′″, Z′″, a″″, A″″, b″″, B″″, c″″, C″″, d″″, D″″, e″″, and E″″; 3) T1 is selected from the group consisting of 1, 2, 3, and 4; and wherein all possible combinations of P3, P4 and T1 comprise the library.
 32. A method of producing a library of compounds comprising: 1) providing

 wherein T1 comprises a labeling tag; 2) reacting a first equivalent of any of the compounds of claims 20 or 22 or morpholine in the presence of a base and a solvent; 3) removing the solvent; and 4) reacting a second equivalent of any of the compounds of claims 20 or 22 or morpholine in the presence of a base and a solvent, with the proviso that said first equivalent and said second equivalent are not both morpholine.
 33. The method of claim 32, wherein T1 is selected from the group consisting of:


34. The method of claim 32, wherein said base comprises potassium carbonate.
 35. A compound selected from claims 1 or 28 comprising demonstration of protein-protein interactions.
 36. A compound selected from claims 1 or 28 comprising a pharmaceutical lead.
 37. A compound selected from claim 28 comprising a pharmacological probe.
 38. A compound selected from any one of claims 1, 21, 23, 25, or 26 comprising a pharmaceutical. 